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Examining Risk Perception and its Influence on 
Treatment Adherence in Those with Type II Diabetes Mellitus 
 
Reid C. Smith 
 
Background: Type 2 diabetes mellitus (T2DM), has quickly become a national 
epidemic.  Adherence to therapies is critical in attempting to ward off complications 
associated with uncontrolled diabetes.  Adherence to therapies remains weak even with 
advancements in treatment options.  Predictors for nonadherence have been studied for 
several decades. Prescription medication risk perception has been measured and 
compared between people who completely abstain from medications to treat previously-
diagnosed conditions and those who decide to treat using medications.  Additionally, 
perceived risk of disease and of routine risks encountered throughout life have been 
related to self-care adherence in patients with T2DM.  The relationship between risk 
perception and self-care adherence is an area needing study. 
Aim: The purpose of this study was to examine the relationship between perception of 
risk and treatment adherence in adults who have T2DM. 
Method: A random sample of 381 subjects being treated for T2DM completed a 
comprehensive Internet-based survey.  Along with demographic characteristics the 
questionnaire contained several scales related to harm and benefit perception, perceived 
threat of diabetes, self-efficacy, and adherence to diabetes-related self-care treatments. 
Results: Significant differences were found in perceived risk of oral hypoglycemics 
between respondents using oral drugs for T2DM vs. those who were not.  Likewise, 
significant differences in risk perception of oral hypoglycemics were observed between 
men and women.  Adherence to self-care treatments was variable, with over one in three 
respondents having poor medication adherence, and the average number of days 
exercised in the week leading up to survey completion was less than three days.  
Adherence to some self-care treatments appears to be significantly related to risk 
perception.  
Conclusion: Individuals with T2DM perceive medications for diabetes and its related 
comorbidities to be of high benefit and low harm.  Adherence to exercise, diet, and 
medication recommendations was relatively low.  Results indicate a potential link 
between risk perceptions and adherence to diabetes-related self-care treatments.  Gaining 
insight into how persons with T2DM perceive the harms and benefits of diabetes-related 
self-care treatments in relation to risks and benefits of other medical and nonmedical 
products and activities may help with other areas of diabetes treatment adherence 
research. 
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CHAPTER 1: INTRODUCTION 
  
 Type 2 diabetes mellitus (T2DM), has quickly become a national epidemic.  It is 
estimated that 10.3% of Americans have T2DM, compared with less than 5% in Japan 
and the United Kingdom (IDF Diabetes Atlas, 2009).  Additionally, approximately 1 out 
of every 8 dollars ($176 billion) spent on medical care in the United States is directly 
attributed to T2DM (American Diabetes Association, 2012).  Adherence to therapies has 
not substantially improved for decades (Vermeire, Hearnshaw, Van Royen, & Denekens, 
2001).  Because DM is projected to affect 48.3 million people in the United States by 
2050 (Narayan, Boyle, Geiss, Saaddine, & Thompson, 2006), improving treatment 
adherence in those with T2DM is of critical importance. 
 Evidence has been collected for several decades that connect health beliefs to 
treatment adherence (DiMatteo, Haskard, & Williams, 2007).  Differences in prescription 
medication risk perception have been detected between those that completely abstain 
from medications for previously diagnosed conditions and those that decide to medicate 
(Slovic, Peters, Grana, Berger, & Dieck, 2007).  Additionally, perceived risk of disease 
and of the environment has been related to treatment adherence in patients with T2DM 
(Shreck, Gonzalez, Cohen, & Walker, 2013).  Understanding the relationship between 
prescription medication risk perception and treatment adherence is an area needing study. 
Aims 
 The goal of this explanatory, descriptive study was to critically test the 
relationship between risk perception and adherence to self-care activities in the context of 
the Health Belief Model (Janz & Becker, 1984).  The research question asked was, “How 
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does risk perception among patients with type 2 diabetes mellitus influence adherence to 
treatments related to diabetes?”  The specific aims of the study were: 
Aim 1: To quantitatively describe risk perception in persons with T2DM.  
Aim 2: To describe levels of adherence for diabetes self-care behaviors, including 
medication use, diet, exercise, foot care, smoking, and self-monitoring of blood 
glucose.  
Aim 3: To examine the relationship between risk perception and adherence to 
diabetes self-care behaviors, including medication use, diet, exercise, foot care, 
smoking, and self-monitoring of blood glucose. 
Significance 
 
 Poor adherence with medications is a critical issue among patients who have 
T2DM.  Increasing rates of treatment plan adherence is critical from both economic and 
public health perspectives. This study adds to existing work in the area.   Additionally, a 
more complete understanding of how risk perception is associated with treatment 
adherence will influence future efforts to create patient education and adherence 
initiatives. As all chronic illnesses are plagued by treatment nonadherence, this area of 
research is potentially applicable to many chronic conditions. 
Health Care Costs and Chronic Disease in the U.S. 
 It is well known that the United States faces a number of challenges related to 
health care, as it ranks 37th in overall efficiency according to the World Health 
Organization (Tandon, Murray, Lauer, & Evans, 2000).  While the available technology 
combined with the training and skill of the United States’ health professionals may be 
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unmatched, health care costs are rising at an unsustainable rate.  Health care costs are 
increasingly consuming a larger share of both private and public assets (“Main economic 
indicators,” 2009).   
 There is increasing incidence and prevalence of debilitating chronic diseases in 
the United States.  Chronic diseases, or those diseases that are long lasting and often 
incurable, currently affect 45% of the U.S. population.  Chronic diseases place 
tremendous strain on health care budgets as they account for 91% of filled prescriptions 
and 81% of all hospital admissions (Partnership to Fight Chronic Disease, 2007).  It is 
reported that chronic diseases account for 70% of American deaths, of which many have 
safe and effective medications with proven morbidity and mortality benefits (Kung, 
Hoyert, Xu, & Murphy, 2008).  Because such a large portion of the United States 
government’s budget is spent on health care through public institutions and programs 
such as the Veterans Health Administration, Indian Health Service, Military Health 
System, Medicare, Medicaid, and State Children’s Health Insurance Programs (S-CHIP), 
it is increasingly clear that the country’s future economic viability requires controlling 
health care costs associated with the progression of chronic disease.  
Type II Diabetes Mellitus  
 A new diagnosis of T2DM is life changing.  Not only does a T2DM diagnosis 
require substantial lifestyle modifications such as changes in diet and an increase in 
regular physical activity, but T2DM also necessitates multiple oral medications for most 
patients and injectable insulin for more severe cases.  Making the decision to start a new 
chronic medication therapy may cause mixed emotions.  For some, taking medication 
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might signify a loss of control, a feeling of getting older, or embarrassment, while for 
others initiating medication may offer a sense of control over a potentially debilitating 
condition (Shoemaker & Ramalho de Oliveira, 2008). 
 For those with a new or existing diagnosis of T2DM, existing therapies in 
conjunction with lifestyle modifications can limit the disease’s potential short-term and 
long-term adverse effects (Warren, 2004). The Centers for Disease Control and 
Prevention (2008) rank diabetes as a leading cause of lower-leg amputations, retinopathy, 
and nephropathy in the United States, all of which are potentially preventable if treatment 
regimens are adhered to.  Regrettably, these substantial risks are not enough to motivate 
some patients to action. More than 20% of patients are nonadherent to therapies, which 
leads to a statistically significant increase in all-cause hospitalization and all-cause 
mortality (Ho, Rumsfeld, Masoudi, McClure,…, & Magid, 2006).     
Risk Perception 
 Risk perception has been measured using the psychometric paradigm approach for 
over three decades (Slovic, 1984).  Measuring risk perception using this approach 
initially yielded quantifiable risk perceptions in nine different dimensions, which consist 
of voluntariness of risk, immediacy of effect, knowledge of risk to those exposed, 
knowledge of risk known to science, control, newness, chronic-catastrophic, common-
dread, and severity of consequences (Fischhoff, Slovic, Lichtenstein, Read, & Combs, 
1978).  Principal components factor analysis of these dimensions identified two factors: 
technological risk and severity.  This early research suggested that it is possible to 
quantitatively measure individuals’ risk perceptions (Fischhoff et al., 1978).   
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 Walker, Caban, and Schechter (2007) created the Risk Perception Survey—
Diabetes Mellitus survey tool, which is based off of the initial work by Fischhoff et al. 
(1978) to measure comparative risk perceptions in a minority, urban population.  This 
was the first health tool developed specifically for measuring risk perception in patients 
with a pre-existing diagnosis of T2DM.  The tool seeks to quantify individuals’ 
perceptions of risks of the disease and of the environment.  While there is research to 
support the hypothesis that risk perception does indeed influence treatment adherence 
(Walker et al., 2007; Shreck, Gonzalez, Cohen, & Walker, 2013; Slovic, Peters, Grana, 
Berger, & Dieck, 2007), the available research does not specifically address the 
relationship between perceived harm and benefit of prescription medications and 
treatment adherence.  
Model of Investigation 
 The Health Belief Model (HBM) has been used for over 50 years and was created 
to try to explain why people generally do not participate in screening tests or partake in 
disease prevention activities for asymptomatic diseases (Janz & Becker, 1984).  The 
model originally consisted of four components: perceived severity, perceived 
susceptibility, perceived benefits, and perceived barriers, but has since been expanded to 
include additional concepts including self-efficacy and locus of control (see Figure 1; 
Rosenstock, Strecher, & Becker, 1988).  An internalized cost-benefit analysis (perceived 
benefits minus perceived barriers) is thought to influence an individual’s likelihood of 
action.  When an individual conducts her/his own cost-benefit analysis, she/he will weigh 
the possible benefits of executing a particular action against the associated costs or risks 
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(e.g. financial costs, side effects, pain; see Janz & Becker, 1984).  The risk of short- and 
long-term consequences of untreated diabetes can be significant, and the potential 
adverse effects of possible therapy options can be devastating.  Thus, perceived risk of 
medications (a barrier to the likelihood of treatment in the HBM) plays an important role 
in an individual’s decision to adhere to medication therapy.  Perceived susceptibility and 
perceived threat can be combined and subsequently measured using the construct of 
perceived threat (Carpenter, 2005).  
 The HBM provides an appropriate framework for adherence research.  The HBM 
predicts health related behaviors and includes many factors that influence medication 
adherence.  Understanding risk perception vis-à-vis HBM may enhance scientific 
understanding of factors contributing to nonadherence, help to improve adherence 
initiatives, and ultimately lead to increased adherence in those with T2DM.  
Figure 1. Adapted Health Belief Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted and modified from Stretcher & Rosenstock (1997). 
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
 The purpose of the present explanatory, descriptive study was to address the 
perceptions of risk and its relationship with self-care adherence in those T2DM.  This 
chapter will review the literature related to risk perception in persons with T2DM and its 
relation to self-care adherence.  The review is structured in accordance with the 
theoretical model of inquiry used to guide this study—the Health Belief Model (Stretcher 
& Rosenstock, 1997).  Using this model, the review describes harm perception and 
benefit perception as a cost-benefit analysis to self-care, perceived threat as a 
combination of perceived severity and perceived susceptibility, and additional factors 
found to influence adherence to self-care behaviors.  
Risk Perception 
 Risk perception has been studied in a variety of ways for many decades.  Starr 
(1969) utilized a psychometric approach when studying risk perception to measure the 
relationship between social benefit and technological risk.  Starr believed that risk 
perception could be measured by using a “revealed preference” approach because society, 
through trial and error, has balanced benefits with acceptable risks of an activity 
(Fischhoff et al., 1978).  Of note, among his many conclusions Starr (1969) suggested 
that the level of risk tolerated for hazards that are undertaken voluntarily (e.g. downhill 
skiing or medication) is similar to the level of risk from disease. 
 In response to Starr’s original work, Fischoff et al. (1978) utilized an “expressed 
preference” approach to understanding risk, which showed that risk perception is 
predictable and quantifiable (Slovic, 1987).  Fischoff et al.’s (1978) conclusions from 
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their groundbreaking work differed slightly from the conclusions reached by Starr.  
Chiefly, activities that are entered voluntarily are considered no less risky than those 
entered involuntary as long as those activities have a perceived equal level of benefit.  As 
highlighted in the introduction, risk perception is believed to fall into nine dimensions.  
Fischoff et al. (1978) concluded that these dimensions can be reduced to two factors: 1) 
high- and low-technology activities, with high-technology activities being those that are 
involuntary, new, poorly understood, and having delayed consequences, and 2) certainty 
of death should an individual be subjected to the activity or condition.  In a review of 
“expressed preference” risk perception research, Slovic (1987) commented that perhaps 
the most important realization is that lay people and experts view risk assessment 
differently, and that lay people often lack certain information regarding hazards, but their 
perception of risk is often much richer and considers concerns that are often forgotten by 
experts.  Thus, health providers must be cognizant of each patient’s individual concept of 
risk when discussing health-related decisions.  Individuals can be both risk averse and 
risk-seeking across differing domains (Weber, Blais, & Betz, 2002).  An individual might 
be risk averse when it comes to financial decisions (e.g. gambling), but risk-seeking when 
making recreational decisions (e.g. camping alone in the woods).  Risk aversion in one 
aspect of life does not coincide to risk aversion in every aspect. 
 Three separate studies have measured risk perception of prescription drugs in the 
countries of Canada (Slovic, Kraus, Lappe, & Major, 1991), Sweden (Slovic, Kraus, 
Lappe, Letzel, & Malmfors, 1989), and the United States (Slovic, Peters, Grana, Berger, 
& Dieck, 2007).  These studies aimed to quantitatively measure the public’s perceptions 
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of benefit and perceptions of harm of prescription drugs for various disease states.  
Additionally, the study provided baseline risk perception data to help measure future 
trends and place prescription drug perceptions in a broader context regarding risk of other 
activities and technologies (Slovic et al., 2007). 
 Overall, in the study conducted in the U.S., prescription medication was perceived 
to be of high benefit and of low risk, which is similar to the results gathered in Canada 
and Sweden (Slovic et al., 2007).  This favorable perception did not hold for all drugs, as 
medications for diet, sleep, and depression were not viewed as positively.  Risk and 
benefit perceptions were different across gender and ethnic categories for several broad 
medication classes.  Cost of medications was the predominant concern regarding 
prescription medications for subjects.  Occurrence of side effects was not only associated 
with increased risk, but side effects were also associated with higher perceptions of 
benefit.  However, subjects who had experienced a recent side effect had less favorable 
medication perceptions than those subjects whom had greater time lapse between side 
effects.  
Diabetes Mellitus 
 In wanting to measure health professionals’ risk perception towards diabetes, 
Walker, Kalten, Mertz, & Flynn (2003) created the Risk Perception Survey for 
Developing Diabetes (RPS-DD) based off of work by Slovic (1987) that was initially 
given to physicians, later to pharmacists (Pinelli, Berlie, Slaughter, & Jaber, 2009), 
women with a history of gestational diabetes (Kim, McEwen, Piette, Goewey, Ferrara, & 
Walker, 2007), and was eventually adapted to the Risk Perception Survey—Diabetes 
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Mellitus (RPS-DM; Walker, E.A., Caban, A., Schechter, C.B., Basch, C.E., Blanco, E., 
DeWitt, T…, & Mojica, G., 2007) for use in patients with a history of diabetes (Walker et 
al., 2007; Shreck et al., 2013). 
 In Walker et al. (2003), physicians showed moderate comparative risk perceptions 
for both disease and environmental risk, believed they had a sense of control over 
developing diabetes, and thought that they were less likely than others to develop 
diabetes.  Similarly, in Pinelli et al. (2009) pharmacists indicated they had moderate 
comparative risk perceptions for both disease and environmental risk.  Pharmacists also 
believed that they were less likely to develop diabetes compared to others and that they 
had more personal control in developing the disease. 
 The RPS-DM was first developed to measure comparative risk perceptions in a 
multiethnic, urban minority sample of patients with T2DM who were participating in a 
study to improve diabetic retinopathy screening rates (Walker et al., 2007).  The 
participants indicated that 42.4% were Hispanic and 44% were Black and was given in 
both English and Spanish versions.  Comparative risk perceptions were statistically 
significant for several demographic variables.  While the RPS-DD and RPS-DM differed 
slightly in language, the authors felt the questions were similar enough to make 
comparisons between this multiethnic, urban minority population and the physician 
sample studied in Walker et al. (2003).  Tests for statistical significance were not 
undertaken, but this patient population had a lower mean score for Personal Control 
(lower scores indicate a feeling of less control), a higher mean score on the Optimistic 
Bias scale (higher scores indicate more optimistic bias), and a higher mean score on the 
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Comparative Environmental Risk scale compared to the physician group (Walker et al., 
2007).  
 In a separate study, the RPS-DM was completed by 526 lower-income, urban 
dwelling participants with diabetes, who were members of the same union/employer 
health benefit plan, and were either current or recent healthcare workers, or their spouses 
(Shreck et al., 2013).  This was the first longitudinal study using the RPS-DM, and 
compared risk perception with diabetes self-care (measured using The Summary of 
Diabetes Self-Care Activities; Toobert, Hampson, & Glasgow, 2000) at baseline and at 1-
year after receiving telephonic or paper behavioral interventions every 4 to 6 weeks 
during the study period.  Compared to the previously mentioned studies, Shreck and 
colleagues used an aggregate risk perception score that combined the subscales found in 
the RPS-DM in their hypotheses.  However, it was indicated that the separate risk 
perception components did have significant associations in a logistic regression model 
with dietary adherence, number of days eating high-fat foods, medication adherence, and 
days participating in specific exercise. 
Medication Adherence in Diabetes 
 To improve the quality and efficiency of the health care system, Berwick, Nolan, 
and Whittington (2008) suggest that the focus must be on the triple aim of improving 
individualized care, improving the overall health of the population, and reducing costs.  
Medication adherence is a term generally defined as the proportion of the time that an 
individual takes a medication as directed (Osterberg & Blaschke, 2005).  Medication 
nonadherence can have drastic consequences for patients’ outcomes, and can be 
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calculated on a range from zero to one hundred percent.  As an example, if a pregnant 
patient only takes a once-daily prenatal vitamin every other day then her adherence 
would be 50%.  Oftentimes in research an adherence value of 80% will be used to 
differentiate those who are adherent versus those who lack adherence (Choudhry et al., 
2009).  This value is arbitrary and has no real clinical significance as some medications 
can be taken less than 80% of the time with no ill effect while others need to be taken 
100% of the time (e.g. drugs for HIV/AIDS) for optimal benefit.   
 It is estimated that the cost of poor medication adherence in the United States 
exceeds $100 billion annually (Dunbar-Jacob & Mortimer-Stephens, 2001).  Medication 
nonadherence is so prevalent throughout this country that focusing on this issue will help 
improve individualized care, improve the overall health of the population, and reduce 
costs. 
 Poor medication adherence has many social, behavioral, and economic 
antecedents (Osterberg & Blaschke, 2005).  Even though much research has been 
directed towards elucidating causal factors, little is known about how to improve 
medication nonadherence (Osterberg & Blaschke, 2005).  Improving adherence rates 
would have tremendous effects on lowering healthcare costs and reducing the risk for 
future adverse health events (Gibson, Song, Alemayehu, Wang, …, & Forma, 2010).  In a 
comprehensive review of barriers to adherence, Gellad, Grenard, and McGlynn (2009) 
state, “The literature on barriers to medication adherence is heterogeneous and of variable 
quality.”  The authors conclude that available data only support policy recommendations 
for the following four modifiable adherence barriers (Gellad et al., 2009): 
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1. Cost-sharing; 
2. Depression (especially in those with diabetes); 
3. Regimen complexity; and 
4. Medication beliefs. 
High quality research is needed to elucidate all of the many contributors to poor 
adherence.  
 In a Cochrane review of literature supporting interventions to enhance 
adherence, Haynes, Ackloo, Sahota, McDonald, and Yao (2008) found three studies 
pertaining to interventions to improve adherence in patients with T2DM that met 
inclusion criteria.  Interventions were intensive (e.g. regular follow-ups via telephone) 
and had variable benefits (e.g. adherence improved, but the clinical marker HbA1c was 
not significantly different).  Despite the increasing research in the area of medication 
adherence, the effectiveness of available interventions to improve adherence is limited 
(Haynes et al., 2008). 
Non-medication Self-Care Adherence in Diabetes  
 In conjunction with medications, it is recommended that those diagnosed with 
T2DM follow several self-care strategies to decrease the risk of complications from 
T2DM.  Diabetes self-care consists of a wide range of activities, which include diet, 
exercise, foot care, and self-monitoring of blood glucose.  Patients that are able to adhere 
to recommended self-care activities are often rewarded with exceptional glycemic control 
and a decrease in complications associated with the disease (Delamater, 2006). 
 Similar to nonadherence concerns with medications, patients are routinely 
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nonadherent to other forms of self-care.  In a nationally representative sample of health 
maintenance organization enrollees (n=4,839; Lin, Katon, Von Korff, Rutter,…,Young, 
2004) only 10% of respondents indicated that they followed a health diet plan, and nearly 
half (47.8%) of respondents exercised no more than 1 day per week.  Similarly one out of 
four individuals indicated that they rarely self-monitor blood glucose as recommended 
(25.8%) and one in five individuals (20.1%) check their feet less than twice weekly (Lin 
et al., 2004). 
 As with medication adherence, causes of nonadherence to the previously 
mentioned self-care activities are multifactorial.  Beliefs play an important role in 
adherence.  Beliefs about the illness and the treatments themselves, self-efficacy, locus of 
control, coping strategies, and perception of relationship with care provider have all been 
associated with self-care adherence (Gherman, Schnur, Montgomery, Sassu, Veresiu, & 
David, 2011).  Additional psychosocial issues that have shown to impact adherence to 
self-care include low levels of family support and depression (Glasgow, Toobert, & 
Gillette, 2001).    
CHAPTER 3: METHODOLOGY 
 The purpose of this explanatory, descriptive study was to address the perceptions 
of risk and its relationship with self-care adherence in those with type 2 diabetes mellitus.  
The research question asked was, “How does risk perception among patients with type 2 
diabetes mellitus influence adherence to treatments related to diabetes?” Specifically, the 
aims of this study are:  
Aim 1: To quantitatively describe risk perception in persons with T2DM.  
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Aim 2: To describe levels of adherence for diabetes self-care behaviors, including 
medication use, diet, exercise, foot care, smoking, and self-monitoring of blood 
glucose.  
Aim 3: To examine the relationship between risk perception and adherence to 
diabetes self-care behaviors, including medication use, diet, exercise, foot care, 
smoking, and self-monitoring of blood glucose. 
 
Figure 2.  Adapted Health Belief Model Including Study Scales 
 
 
Variable Definitions 
  
 Please reference the model in Figure 2 when reading the definitions below.  
 
Risk Perception 
 Conceptual Definition  
 Risk has many different conceptual definitions in the literature (Aven & Renn, 
2009).  Thus, it is difficult to conceptually define risk using one definition that 
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encompasses all forms of risk.  For the purpose of this research, the following definition 
of risk by Renn (2005) will be utilized: “an uncertain consequence of an event or an 
activity with respect to something that humans value.” It is key to note that risks are only 
taken for something that humans’ value.  Assuming humans are rational, risks are only 
taken if there is potential for a reward.  Furthermore, “an uncertain consequence” can be 
either positive or negative.  Thus, risk perception will be gauged by measuring both 
perception of harm and benefit.      
 Operational Definition 
 Risk perception was measured using the technique pioneered in Slovic et al. 
(1989) and used most recently in a large study in the United States (Slovic et al., 2007).  
These studies used a technique that has previously been described as the psychometric 
paradigm.  This technique assumes to quantitatively measure individuals’ risk 
perceptions of technologies and activities.  To measure harm perception, survey 
participants were asked to answer the following: “To what extent would you say that 
people who are exposed to this item are at risk of experiencing personal harm from it?”  
The possible responses ranged from 1 (They are not at risk) to 7 (They are very much at 
risk).  The rating scales were anchored by the two descriptive phrases, but did not include 
descriptive phrases for intermediate responses.  
 Benefit perception was measured with the same technique used to measure harm 
perception, as described above.  The benefit question asked was, “In general, how 
beneficial do you consider this item to be?”  The possible responses will range from 1 
(Not at all beneficial) to 7 (Very beneficial).  Equivalent to the harm perception response 
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categories, the benefit perception rating scales were anchored by the two descriptive 
phrases, but did not include descriptive phrases for intermediate responses.  The benefit 
perception question had the same exact items (i.e. prescription drugs, technologies, and 
activities) as the risk perception question.  Approximate time to complete the harm and 
benefit questions was twenty minutes.  
 Risk perceptions were gathered for various hazardous items, including: the 
individual item “prescription drugs”, 23 additional pharmaceutical items by category (e.g. 
Drugs for Cholesterol) or specific drug types (e.g. aspirin), 6 medical tests or procedures 
(e.g. heart surgery, acupuncture, and medical x-rays), and 16 nonmedical hazards (e.g. 
cell phones, cigarette smoking, and high-sugar foods).  See Appendix 1 for a complete 
list of the hazardous items. Collecting nondrug and nonmedical hazard risk perception 
data allows for placing the prescription drug risk perception in a broader context.   
     For this study, some of the pharmaceutical items were eliminated from the original 
item list in order to reduce participant survey fatigue.  “Drugs for diabetes”, “Over-the-
counter (OTC) drugs”, “Drugs for neuropathy” (nerve pain), and “Influenza vaccine” will 
be added to the pharmaceutical items list. “Self-Monitoring of Blood Glucose (blood 
glucose lancet)” will be added to the medical procedures list.  Finally, “moderate-
intensity exercise”, “electronic cigarettes”, and “high-sugar foods” will be added to the 
nonmedical hazards list.  
Perceived Threat 
 Conceptual Definition 
 Perceived threat is defined as a combination of the perceived severity and 
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perceived susceptibility constructs in the Health Belief Model (Sturges & Rogers, 1996).  
Specifically, perceived threat is an individual’s perception of an anticipated harm that is 
derived from a cognitive appraisal of an event or cue (Carpenter, 2005). 
 Operational Definition 
 Perceived threat was measured using the threat subscale found in the Cognitive 
Appraisal of Health Scale (CAHS; Kessler, 1998).  The Kessler (1998) study used an 
exploratory factor analysis on an original scale of 31 items with four hypothesized 
subscales that was given to a sample of 201 women with breast cancer.  The threat 
subscale was found to consist of 5 items that had an internal consistency alpha coefficient 
of 0.85.  Similarly, Carpenter (2012) used an exploratory factor analysis on 80 
individuals with diabetes.  In this population the same 5 items were found to fit together 
in the threat subscale with an alpha coefficient of 0.69.   
 Although in previous studies participants were asked to complete the entire 
CAHS, it was decided to decrease respondent burden by only including the threat 
subscale as mentioned in Kessler (1998) and Carpenter (2012). The threat subscale 
consists of 5 items that had 5 possible response categories from 1 (strongly disagree) to 5 
(strongly agree).  The threat subscale was scored by adding the 5 answers together for a 
total range of possible scores from 5-25.  See Appendix 2 for a list of the questions.  
Adherence 
 Conceptual Definition 
 For this study, adherence will be defined as the rate at which recommended self-
care tasks for T2DM were followed.  Recommended self-care tasks were taken from the 
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“Standards of Medical Care in Diabetes—2013” by the American Diabetes Association.  
The recommended self-care tasks included medication management, diet, exercise, foot 
care, smoking, and self-monitoring of blood glucose (SMBG).  
 Operational Definition 
 Adherence to medications will be measured using the Morisky Scale (Morisky, 
Green, & Levine,1986) and adherence to diet, exercise, foot care, smoking, and SMBG 
will be measured using the Summary of Diabetes Self-Care Activities (SDSCA; Toobert, 
Hampson, & Glasgow, 2000). 
 The Morisky Medication Adherence Scale (MMAS) is an eight- or four-item 
instrument initially tested for validity in a sample of 290 patients with hypertension 
(Morisky, Green, & Levine, 1986).  The original 4-item scale was derived from a study 
by Green, Levine, & Deeds (1975).  The 4-item MMAS was originally found to have a 
correlation coefficient of 0.61, which is not surprising considering nonadherence factors 
for medications is often multifactorial (Morisky et al., 1986).  The predictive validity of 
the 4-item MMAS was found to have a linear relationship.  Respondents that indicated 
high adherence based on the MMAS were significantly more likely to have controlled 
blood pressure compared to those who scored low on the 4-item MMAS (r=0.58; P<0.01; 
Morisky et al., 1986).  While the 4-item MMAS has been shown to highly correlate with 
adherence rates, it is suggested that four items are too few to capture the complexity of 
nonadherence; thus, the 4-item MMAS is to be used in the clinical setting and the 8-item 
MMAS be used for research purposes (Morisky & DiMatteo, 2011). 
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 The 4-item MMAS has been utilized to measure medication adherence in T2DM 
(Krapek et al., 2004).  A statistically (p=0.0003) and clinically significant relationship 
was measured between Morisky scores and HbA1c (a marker of long-term control), as 
those with good adherence (Morisky score ≥ 3) had a 10% lower HbA1c (8.67% vs. 
7.74%) compared to those with poor adherence (Morisky score ≤ 2; Krapek et al., 2004).  
In a separate study of patients with T2DM, the 8-item MMAS was found to have 
moderate internal consistency and excellent test-retest reliability.  A statistically 
significant relationship was measured between the 8-item MMAS and HbA1C (Lee et al., 
2013).  See Appendix 3 for a list of the questions in the 8-item MMAS.   
 Several scales have been created over the past decades to measure guideline 
adherence to self-care activities (Bradely, 1994).  The Summary of Diabetes Self-Care 
Activities (Toobert, Hampson, & Glasgow, 2000) is an 11-item (revised from an original 
25-item) survey tool that measures adherence to diet, exercise, SMBG, smoking, and foot 
care.  In a comprehensive review of 7 studies, Toobert et al. (2000) suggested that the 
SDSCA had adequate test-retest and internal reliability, and had evidence to support its 
validity and sensitivity to change.  Toobert et al. (2000) revised the initial 25-item scale 
down to the 11-item scale due to the following: 
1) consistency in mean values across studies; 
2) sufficient variability and lack of ceiling or floor effects; 
3) temporal stability;  
4) internal consistency;  
5) predictive validity;  
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6) sensitivity to change;  
7) ease of scoring; and 
8) ease of interpretation. 
Additionally, items were added to measure smoking and foot care, and items measuring 
medication management were eliminated due to ceiling effects and lack of variability in 
responses from subjects. 
 Because it is recognized that different factors of self-care do not highly correlate  
(i.e. an individual may be highly adherent to a diabetes-specific diet, but does not 
exercise; Orme & Binik, 1989), scores for the self-care activities in the SDSCA are 
scored individually.  The SDSCA limits recall bias by asking respondents to remember 
how many days out of the last 7 they followed specific clinical recommendations.  Thus, 
the SDSCA is not a long-term marker of adherence per se, but estimates adherence to 
self-care standards based on self-care during the previous week.  See Appendix 4 for 
questions in the SDSCA.  
Self-Efficacy 
 Conceptual Definition 
 For this study, self-efficacy was one’s beliefs that he or she was able to perform 
the necessary tasks associated with diabetes self-care. 
 Operational Definition  
 Diabetes self-efficacy was tested using the Diabetes Empowerment Scale-Short 
Form (DES-SF; Anderson, Fitzgerald, Gruppen, Funnell, & Oh, 2003).  The DES-SF is 
an 8-item questionnaire that was condensed from the 28-item Diabetes Empowerment 
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Scale (DES; Anderson, Funnell, Fitzgerald, & Marrero, 2000).  Internal reliability of the 
DES-SF was found to be acceptable (α= 0.85) using the data from the sample originally 
used to create the DES, and was found to be acceptable (α= 0.84) in an additional study 
of 229 subjects (Anderson et al., 2003).  Initial measures of content validity appear 
positive as higher DES-SF scores (higher self-efficacy) was associated with lower 
HbA1C.  However, changes in the DES-SF and HbA1C were not significant correlated 
after a 6-week intervention (Anderson, Funnell, Nwankwo, Gillard, Fitzgerald, & Oh, 
2001). 
 The DES-SF has 8 questions with Likert-type responses from 1 (strongly 
disagree) to 5 (strongly agree).  The score is obtained by adding the scores from the items 
and then dividing by the number of completed items leading to a range of possible scores 
from 1 to 5.  The DES-SF takes approximately 5 minutes to complete.  See Appendix 5 
for the questions in the DES-SF. 
Demographic Characteristics and Additional Variables Measured 
 Demographic data collected consisted of: age, gender, duration of diabetes, 
relationship status, household income, and education.  Additional variables collected 
included: prior visit with a Certified Diabetes Educator (CDE), hemoglobin A1C, height, 
weight, current insulin and oral diabetes medication use status, and history of side effects 
and side effect severity.  
The data was defined operationally as follows: 
Age 
 Age was collected by self-report, and recorded in years. 
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Gender 
 Gender was collected by self-report, and recorded as male or female. 
Duration of Diabetes 
 Duration of diabetes was collected by self-report, and was collected by having 
subjects report age at T2DM diagnosis. 
Relationship Status 
 Relationship status was collected by self-report.  Relationship status was recorded 
for the following categories: single, married, divorced, widowed, or committed 
relationship (unmarried).   
Annual Household Income 
 Annual household income was collected by self-report.  Annual household 
income was recorded for the following categories:  
less than $10000 
$10000-$19999 
 $20000-$29999 
 $30000-$39999 
 $40000-$49999 
 $50000-$59999 
  $60000-$69999 
 $70000-$79999 
  $80000-$89999 
 $90000-$99999 
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 $100,000-$109,999 
 $110,000-$119,999 
 $120,000-$129,999 
 $130,000-$139,999 
 $140,000-$149,999 
 greater than or equal to $150,000 
Education 
 Education was collected by self-report.  Education was reported for the following 
categories: less than high school; high school graduate or GED; some college, 
community, or technical school; community or technical school graduate; college 
graduate, master’s degree, doctoral degree.  
Prior Visit with a CDE 
 Prior visit with a CDE was collected by self-report.  Prior visit with a CDE was 
reported as yes or no.  
Hemoglobin A1C 
 Hemoglobin A1C (A1C) was collected by self-report.  The most recent date and 
level for Hemoglobin A1C was recorded.  
Height 
 Height was collected by self-report, and recorded in feet and inches. 
Weight 
 Weight was collected by self-report, and recorded in pounds. 
Current Insulin Use 
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 Current insulin use was collected by self-report, and was recorded as yes or no. 
Current Oral Diabetes Medication Use 
 Current oral diabetes medication use was collected by self-report, and was 
recorded as yes or no. 
Side Effect History 
 Side effect history was collected by self-report, and was recorded as history in the 
past 5 years as yes, no, or unsure for “all medications”, and will be recorded for 
“diabetes-specific medications” as yes, no, or unsure if caused be diabetes medications.  
Overall Side Effect Severity 
 Overall side effect severity was collected by self-report, and was recorded for the 
previous 5-year span as not sure, mild, moderate, or severe. 
Diabetes Medication Side Effect Severity 
 Diabetes medication side effect severity was collected by self-report, and was 
recorded for the previous 5-year span as not sure, mild, moderate, or severe. 
 
Procedure 
 This study was conducted using survey methods. The foremost purpose of the 
study was to address the perceptions of risk and its relationship with self-care adherence 
in those with T2DM.  
To be included in the data set, respondents had to meet the following criteria: 1) 
age > 21 years, 2) diagnosis of T2DM for at least 1 year, 3) the ability to read, write, and 
understand English, 4) the ability to make personal medical decisions, and 5) and 
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receiving care at an Essentia Health facility.  Because the literature suggests that 
adherence to medicines in chronic conditions decreases after six months to a more 
consistent long-term rate (Osterberg & Blaschke, 2005) and A1C is an indicator of blood 
glucose control over the previous three months, participants must have an existing T2DM 
diagnosis for at least one year prior to study inclusion.  The sample excluded pregnant 
women,  justified as the additional institutional review board requirements needed to 
include pregnant women were deemed too burdensome for the purposes of this study.  
After institutional review board approval was obtained from both the University 
of Minnesota and Essentia Health, subjects meeting inclusion criteria were identified and 
emailed a Qualtrics survey link.  The surveys were used to collect empirical data on 
treatment adherence, harm and benefit perception, perceived threat of T2DM, diabetes 
knowledge, self-efficacy, and demographic variables.  The data collected rendered 
descriptive statistics as well as logistic coefficients that help to identify statistically 
significant (p < .05) relationships between risk perception, other independent variables, 
and adherence. 
 The time to complete the survey was estimated to be less than 20 minutes. To 
maintain confidentiality, subject identifiers were not included on the surveys. All 
completed surveys were electronically submitted directly to a Qualtrics account under the 
control of the Essentia Institute of Rural Health. All data was kept in a password secured 
electronic database maintained by the investigator.  All data was analyzed using 
Statistical Package for Social Sciences version 20 (IBM, 2011). 
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An approach to calculating sample sizes for logistic regression has not reached 
consensus (Demidenko, 2007).  Green (1991) asserts that a rule-of-thumb equation of the 
form N ≥ A+Bm   (where A is a constant related to effect size, B is a minimum ratio of 
subjects-to-predictors, and m is equal to the number of predictors) shows a degree of 
agreement with actual power analysis results and is useful for research using typical 
effect sizes, an alpha of 0.05 and a power of 0.80.  A form of the above equation, N > 50 
+ 8m (Green, 1991), was used to predict sample size, and because the outcome is binary 
(adherent or nonadherent) N was multiplied by the expected proportion of events 
(Motulsky, 2010, p. 371).  
     To estimate sample size four predictor variables (harm perception, benefit perception, 
perceived threat, and self-efficacy) was used.  Additional demographic variables were 
used as control factors in the logistic regression models.  As adherence to chronic 
medications for diabetes is estimated to be near 75% (Rubin, 2005), N from the above 
equation was multiplied by 4 (Motulsky, 2010).  Thus, the estimated number of required 
participants is 328 (N>4*[50+8*4]) 
 
CHAPTER 4: RESULTS 
     Analysis of data was preceded by searching for outliers and improbable values. This 
was achieved both by viewing descriptive statistics and frequencies and by visually 
examining for missing data. Missing data were random without any identifiable pattern. 
Cases not meeting inclusion criteria (e.g., age < 21 years, no T2DM diagnosis) were 
removed. Listwise exclusion of cases was used in analyses.  The purpose of this 
   28 
 
explanatory, descriptive analysis is to address the perceptions of risk and its relationship 
with self-care adherence in those with type 2 diabetes mellitus. 
Sample 
 The explanatory, descriptive study was based on 381 subjects who had received 
T2DM care within the previous three years at an Essentia Health facility and had an 
email address on file.  A total of 5011 surveys were initially emailed out and 4682 emails 
reached an email inbox (318 emails were returned as being not true email addresses; 
unable to account for spam or junk email automated responses).  Of the 4682 emails that 
reached an email inbox there were 541 returned surveys for a return rate of 11.6% 
(541/4682).  After eliminating surveys that were returned blank or with an obvious 
intention to not continue with the survey there were 430 completed surveys for a response 
rate of 9.2% (430/4682).  After eliminating surveys that did not meeting inclusion criteria 
(e.g. diagnosis of T1DM, duration of T2DM >=1 year) the final sample size was 381 
(8.1%).  Please see Figure 3. 
Characteristics of the sample (Table 1) included a mean age of 60.4 years (range 
28-89), with nearly equal numbers of men and women (n=195 and 183, respectively).  A 
majority of subjects were married (70.5%), had some amount of post high school 
education (87.2%), and had an annual household income of greater than $60,000 (51%).  
Most subjects (80.7%) responded that they had visited with a certified   
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Figure 3.  Response Flow Chart 
 
 
 
diabetes educator in the past, and 40.2% of subjects have been diagnosed with T2DM for 
less than 5 years.  Greater than half of the subjects (59%) had controlled T2DM 
(HbA1C<=7.0%) with a mean length of time since last HbA1C test of 87 (SD=88) days. 
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Table 1: Sample Characteristics 
  N % 
Age 
M=60.4 (SD=11.2) 
Range: 28-89 
<39 
40-59 
>60 
 
 
19 
148 
214 
 
 
5.0 
38.8 
56.2 
Gender Male Female 
195 
183 
51.2 
48 
Relationship 
Status 
Single 
Married 
Divorced 
Separated 
Widowed 
Committed relationship 
(unmarried) 
43 
268 
30 
5 
21 
13 
11.3 
70.5 
7.9 
1.3 
5.5 
3.5 
 
 
Educational 
Level 
Less than high school 
High school graduate or 
GED 
Some college, 
community, or   
technical school 
Community or technical 
school graduate 
College graduate 
Masters degree 
Doctoral degree 
4 
44 
 
91 
 
 
69 
 
      107 
51 
10 
1.1 
11.7 
 
24.2 
 
 
18.4 
 
      28.5 
13.6 
2.7 
Annual 
Household 
Income 
<$30,000 
$30,000-$59,999 
$60,000-$89,999 
>=$90,000 
77 
110 
97 
97 
20.2 
28.9 
25.5 
25.5 
T2DM 
Duration 
M=8.9 years (SD=8.4) 
Range: 1-49 
<5 years 
5-10 years 
>10 years 
 
 
153 
100 
128 
 
 
40.2 
26.2 
33.6 
BMI M=33.9 (SD=7.4) Range:18.6-77.1 
  
HbA1C 
M=6.9 (SD=1.2) 
Range: 5.1-13.0 
<7% 
>=7% 
 
 
156 
108 
 
 
59 
41 
Prior Visit 
with Certified 
Diabetes 
Educator 
Yes 
No 
Unsure 
305 
51 
22 
80.7 
13.5 
5.8 
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Oral DM Med 
Use 
Yes 
No 
282 
99 
74.0 
26.0 
Insulin Use Yes No 
114 
267 
29.9 
70.1 
History of DM 
Med Side 
Effects 
 
DM Med Side 
Effect History 
Yes 
No 
Unsure 
 
Mild 
Moderate 
Severe 
76 
165 
41 
 
29 
37 
10 
27 
58.5 
14.5 
 
38 
48.7 
13.2 
History of 
Med Side 
Effects 
 
Medication 
Side Effect 
Severity 
Yes 
No 
 
 
Mild 
Moderate 
Severe 
183 
195 
 
 
80 
69 
33 
48.4 
51.6 
 
 
44.0 
37.9 
18.1 
  
Perceived Threat Appraisal 
     Perceived threat of diabetes was calculated as a summated score of the Perceived 
Threat Subscale of the Cognitive Appraisal of Health Scale.  The scale had a possible 
range of scores between 5-25 with perceived threat of diabetes increasing with score.  
Respondents reported a minimum of 5 with a maximum of 24, a mean of 14.2 (SD=4.6), 
and a median of 15.  Using mean score as a cutoff, it was observed that 49.9% of subjects 
considered themselves to have a lower perceived threat of diabetes, while 50.1% of 
subjects had a higher perceived threat.  The Cronbach’s alpha for this scale in this sample 
was 0.859.  All 381 subjects completed the scale. 
Self-Efficacy 
     Diabetes self-efficacy was tested using the Diabetes Empowerment Scale-Short Form.  
The scale is scored on a 1 to 5 scale calculated as an average of the responses to 8 
questions with a higher score indicating higher self-efficacy. In this study it was observed 
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that the subjects reported a minimum of 1 with a maximum of 5, a mean of 3.8 
(SD=0.61) and a median of 3.88.  Using mean score as a cutoff, it was observed that 42% 
of subjects considered themselves to have a lower self-efficacy for taking care of their 
T2DM, while 57.7% of subjects had a higher self-efficacy.  One subject (0.3%) did not 
answer the questions for this scale.  The Cronbach’s alpha for this scale in this sample 
was 0.814, and 380/381 subjects completed the scale.   
Aim 1: Quantitative Description of Risk Perception 
     Risk perception was measured by having respondents rate the risk of 44 items 
comprised of 24 drug items, 6 medical procedures, tests, or device items, and 14 
nonmedical hazard items (see Appendix 1).  Risk perception (perceived benefit minus 
perceived harm) was measured by asking subjects to separately judge possible harm and 
benefits of all items on a semantic differential rating scale from 1 (They are not at risk; 
Not at all beneficial) to 7 (They are very much at risk; Very beneficial).  The harm and 
benefit scores all ranged from 1 to 7.  Of the 88 total questions—each of the 44 items 
were asked twice: once for benefit and once for harm—no item was answered by 
everyone.  The mean number of respondents per item was 376 (98.7%) with a range of 
370 to 379 (97.1% to 99.4%).   
          The mean harm perceptions of the 44 items can be found in Figure 4.   An item 
farther from the y-axis (closer to 7) was perceived to have more risk for those that come 
into contact with it.  Questions were asked on a semantic differential scale, with no 
numbers indicating possible responses between 1 to 7.  Therefore, the x-axis of Figure 4 
is not labeled at integer intervals. The items deemed to present the lowest level of 
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potential harm were self-monitoring of blood glucose, prostate tests, mammograms, 
vitamin pills, and moderate intensity exercise. Cigarette smoking, high fat foods, high 
sugar food, pesticides, and electronic cigarettes were rated as having the highest potential 
for harm for those that come into contact with the object/activity. 
     Mean benefit perceptions can be found in Figure 5.  An item farther from the y-axis 
(closer to 7) was deemed to be more beneficial to those who come into contact with it.  
The items perceived to have the lowest level of benefit were cigarette smoking, electronic 
cigarettes, high sugar foods, high fat foods, and genetically modified foods. Self-
monitoring of blood glucose, heart surgery, insulin, mammograms, and medical x-rays 
were considered to provide the highest level of benefit.   
     As noted earlier, risk perception was defined as perceived benefits minus perceived 
harms.  The differences in risk perception of all items rated are presented in Figure 6.  
Items with scores less than zero were perceived to have more harm than benefit.  Items 
with scores above zero were perceived to have more benefit than harm.   
Another representation of risk perception is presented in Figure 7.  Harm and 
benefit were placed on the x-and-y-axis, respectively, creating four harm/benefit 
quadrants:  low harm-low benefit; low harm-high benefit; high harm-high benefit; and 
high harm-low benefit.  Most of the pharmaceutical items are found in the low harm, high 
benefit quadrant, while cigarette smoking, high sugar foods, and high fat foods are found 
in the high harm, low benefit quadrant. 
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Figure 4. Harm Perception Mean Ratings by Respondents Who Have Type 2 
Diabetes (n for each item = 370-379)1,* 
 
 ______________________________________________________________________ 
1. Questions were asked on a semantic differential scale, with no numbers indicating possible responses 
between 1 and 7.  Therefore, the x-axis of Figure 4 is not labeled at integer intervals.  
• Indicates a drug product indicated to treat the labeled condition. 
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Figure 5.  Benefit Perception Mean Ratings by Respondents Who Have Type 2 
Diabetes (n for each item = 370-379)1,*    
_____________________________________________________________________________ 
1. Questions were asked on a semantic differential scale, with no numbers indicating possible responses 
between 1 and 7.  Therefore, the x-axis of Figure 5 is not labeled at integer intervals.  
• Indicates a drug product indicated to treat the labeled condition. 
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Figure 6. Calculated Risk Perception Ratings (Benefit minus Harm) by Respondents 
Who Have Type 2 Diabetes (n for each item = 370-379)1,* 
______________________________________________________________________ 
1. Questions were asked on a semantic differential scale, with no numbers indicating possible responses 
between 1 and 7.  Therefore, the x-axis of Figure 6 is not labeled at integer intervals.  
* Indicates a drug product indicated to treat the labeled condition. 
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Figure 7. Plot of Mean Benefit and Harm Perception by Respondents Who Have 
Type 2 Diabetes (n for each item = 370-379) 
 
Black= Pharmaceutical Products; Red=Medical Hazards; Blue= Nonmedical Hazards 
Risk Perception Differences by Age 
  Comparisons were made between those who were 60-years/old and younger with 
those who were older than 60 years of age.  Due to the density of the data points, the 
charts were separated into three separate charts that highlight differences in (1) 
pharmaceutical products, (2) nonmedical hazards, and (3) medical procedures, tests, and 
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devices.  The comparisons can be found in Figures 8, 9, and 10.  Because of the density 
of pharmaceutical products in the “High Benefit-Low Harm” quadrant, only select 
products were included in Figure 10. Pairwise differences between harm, benefit, and risk 
perceptions are compared in Table 2 for respondents younger or equal to 60 years of age 
and those older than 60 years old. As highlighted in Table 2, statistical differences were 
only seen with four items (GM Foods, Heart Surgery, Herbal Medicines, and Artificial 
Sweeteners).  
 Pairwise comparisons between individual groups used Mann-Whitney U with 
multiplicity controlled for by using the Šidák multitest correction to keep the 
experimentwise error rate at α<0.05 (Abdi, 2007).  Abdi (2007) describes the Šidák 
calculation as follows:  
1) alphaPC = 1.0 – (1.0 – alphaFW)1/k  
Where alphaPC is the per comparison alpha, alphaFW is 
the familywise alpha, and k is the number of comparisons. 
 
Table 2. Significantly Different Harm, Benefit, and Risk Perceptions by 
Respondents Less-Than-or-Equal-to 60 Years Old and Those Greater-Than 60 
Years Old 
  
Age (years) N 
Mean 
Rank z score p-value* 
Harm Heart Surgery 
<=60 185 210.09 
-3.629 0.0003 
>60 193 169.76 
Harm GM Foods 
<=60 186 210.76 
-3.773 0.0002 
>60 192 168.91 
Benefit Artificial Sweeteners 
<=60 187 171.1 
-3.302 0.00096 
>60 191 207.51 
Risk Herbal Medicines 
<=60 183 205.94 
-4.091 0.00004 
>60 183 161.06 
Risk Artificial Sweeteners 
<=60 185 169.01 
-3.372 0.0008 
>60 190 206.49 
Risk GM Foods 
<=60 186 186.48 
-3.425 0.00062 
>60 189 189.49 
*Šidák Cutoff=0.0011 
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Figure 8. Plot of Mean Benefit and Harm Perception of Nonmedical Hazards by 
Respondents Less-Than-or-Equal-to 60 Years Old and Respondents Greater-Than 60 Years 
Old Who Have Type 2 Diabetes 
 
Figure 9. Plot of Mean Benefit and Harm Perception of Medical Hazards by Respondents 
Less-Than-or-Equal-to 60 Years Old and Those Greater-Than 60 Years Old Who Have 
Type 2 Diabetes* 
 
 
 
 
 
 
 
 
*The y-axis (benefit) was shortened  
from 1-7 to 3-7 to aid in viewing. 
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Figure 10. Plot of Mean Benefit and Harm Perception of Pharmaceutical Products by 
Respondents Less-Than-or-Equal-to 60 Years Old and Those Greater-Than 60 Years Old 
Who Have Type 2 Diabetes** 
 
**The x- (harm) and y- (benefit) axes were shortened to aid in viewing. 
*Drugs for listed condition 
 
 
Risk Perception Differences between Users/Nonusers of Medications 
      Differences between harm, benefit, and risk perceptions are compared below for 
respondents using oral T2DM medications vs. respondents not using oral T2DM 
medications, those using insulin vs. not using insulin, and males vs. females.  
      As noted in the demographics section, 74% (n=282) of the sample was currently 
using oral T2DM medications.  It was hypothesized that those who are using oral T2DM 
medications would perceive the threat of those medications differently than those not 
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using these particular medications. Outcomes of the Mann-Whitney U test between oral 
T2DM medications users and nonusers are presented in Table 3.  Statistically significant 
differences were found for both risk and benefit ratings of oral DM drugs, with 
respondents who are using these medications perceiving higher net benefit than 
respondents who were not using these medications.     
 
Table 3. Perception of Oral DM Drugs in Those with Type 2 Diabetes 
 
 Use Oral 
DM Meds N Mean Rank z score p-value* 
Risk Oral DM 
Drugs 
Yes 
No 
275 
98 
196.15 
161.15 -2.782 .005 
Benefit Oral 
DM Drugs 
Yes 
No 
278 
99 
197.29 
165.71 -2.617 .009 
Harm Oral DM 
Drugs 
Yes 
No 
278 
98 
184.55 
199.70 -1.216 .224 
*Šidák Cutoff=0.017 
 
 
     Among the 381 respondents, 114 (29.9%) indicated that they were currently using 
insulin to help treat T2DM.  It was hypothesized that those using insulin to treat diabetes 
would perceive the threat of insulin differently than those that were not using insulin.  
Outcomes of the Mann-Whitney U between insulin users vs. nonusers are presented in 
Table 4.  While the p-values for harm insulin and risk of insulin between insulin users 
and nonusers were <0.05, none of the tests were deemed significant after using the Šidák 
correction to limit the potential for a Type I error.   
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Table 4. Perception of Insulin in a Sample of Those with 
Type 2 Diabetes 
 Use 
Insulin? N 
Mean 
Rank z score p-value* 
Harm Insulin Yes 
No 
113 
263 
169.68 
196.59 -2.240 .025 
Risk Insulin Yes 
No 
113 
260 
204.42 
179.43 -2.079 .038 
Benefit Insulin Yes 
No 
113 
263 
194.81 
185.79 -0.808 .419 
*Šidák Cutoff=0.017 
 
 
Risk Perception Differences between Genders 
     The sample consisted of 51.6% males and 48% females.  Mann-Whitney U with a 
Šidák correction to prevent a Type I error was used to compare differences in perceived 
threat of drug, medical, and nonmedical hazards.  Please see Tables 5 and 6 for a list of 
statistically significant items.  A higher mean rank for harm items indicated more 
perceived harm and a higher mean rank for benefit items indicates a higher perceived 
benefit.  Of note, the perception of the benefits of oral DM medications, neuropathy 
medications, and self-monitoring of blood glucose was significantly greater in females 
than males.   
Table 5. Significantly Different Harm Perceptions between Men 
and Women in a Sample of Those with Type 2 Diabetes 
 
Gender N 
Mean 
Rank z score p-value* 
Harm GM Foods 
Female 182 214.29 
-4.623 <0.00001 Male 193 163.21 
Harm Nuclear  
Power Plants 
Female 
Male 
183 
193 
218.47 
160.08 -5.283 <0.00001 
Harm Air Travel 
Female 183 207.6 
-3.390 0.000100 Male 193 170.39 
*Šidák Cutoff=0.0011 
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Table 6. Significantly Different Benefit Perceptions between Men 
and Women in a Sample of Those with Type 2 Diabetes 
 
Gender N 
Mean 
Rank z score p-value* 
Benefit GM Foods 
Female 181 162.38 
-4.519 0.00001 
Male 193 211.06 
Benefit Nuclear  
Power Plants 
Female 181 165.65 
207.99 -3.840 0.000123 Male 193 
Benefit Oral DM Drugs 
Female 182 208.12 
-3.794 0.000148 
Male 192 167.96 
Benefit Neuropathy  
Female 182 206.98 
-3.580 0.000344 
Male 191 167.96 
Benefit SMBG  
Female 182 204.76 
-3.496 0.000472 
Male 192 171.14 
Benefit Epilepsy  
Female 178 203.7 
-3.410 0.00065 
Male 191 167.57 
Acupuncture 
Female 178 203.31 
-3.351 0.0008 
Male 190 166.88 
*Šidák Cutoff=0.0011 
 
Risk perception and Side Effects 
     Respondents were asked if they had experienced side effects to diabetes medications 
or other prescription medications over the previous 5 years.  Regarding T2DM 
medications specifically, 101 (26.7%) reported having experienced side effects related to 
diabetes medications, 227 (60.1%)  denied having experienced side effects, and 50 
(13.2%)  were unsure.  Respondents indicating that they were unsure if they have 
suffered any prescription medication side effects were excluded from the following 
analysis. 
     Data were filtered to allow for analysis of respondents who were currently taking an 
oral DM drug.  A Mann-Whitney U test comparing respondents who had experienced 
T2DM medication-related side effects and those who had not was performed, comparing 
differences in Morisky scores and in perceptions of harm, benefit, and risk of oral DM 
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drugs.  A statistical difference was noted in perceived harm and perceived risk of oral 
DM drugs, but not in perceived benefit or the 8-Item Morisky Medication Adherence 
Scale.  See Table 7 for relevant p-values.  A subsequent Kruskal-Wallis One-Way 
Analysis of Variance was performed to test for differences between three groups 
separated by severity levels of side effects (mild, moderate, and severe) with the same 
independent variables.  This test yielded no statistically significant differences. 
 
Table 7. Perception of Oral DM Drugs in Those Taking an Oral DM Drug 
between Those who Have Experienced versus Have Not Experienced Side 
Effects 
 DM Med 
Side Effects? N 
Mean 
Rank z score p-value* 
Harm Oral DM 
Drugs 
Yes 
No 
75 
164 
148.39 
107.02 -4.427 .000 
Risk Oral DM 
Drugs 
Yes 
No 
75 
161 
94.7 
129.59 -3.715 .000 
Morisky Yes No 
76 
165 
104.94 
128.40 -2.475 .013 
Benefit Oral DM 
Drugs 
Yes 
No 
76 
162 
115.78 
121.25 -.613 .540 
*Šidák Cutoff=0.0127 
 
   
A Mann-Whitney U test was performed among those respondents who indicated that they 
were currently using insulin (no =53; yes =43).  No statistical differences (p>0.05) were 
found between the two groups when comparing Morisky scores, perceived harm, benefit, 
or risk of insulin.   
     After filtering the data for only respondents who were either taking insulin or oral DM 
medications, a Mann-Whitney U test was conducted to compare Morisky scores, 
perceived harm, benefit, and risk of prescription drugs in respondents who had 
experienced vs. had not experienced side effects.  Statistically significant differences 
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were seen between these two groups regarding perceived harm and perceived risk of 
prescription drugs.  See Table 8. 
 
Table 8.  Perception of RX Drugs in Those Taking either an Oral DM Drug or 
Insulin between Those who Have Experienced versus Have Not Experienced 
Side Effects    
 Med Side 
Effects? N 
Mean 
Rank z score p-value*  
Harm Rx Drugs Yes No 
183 
194 
210.61 
168.61 -3.834 .000 
Risk Rx Drugs Yes No 
183 
190 
168.48 
204.84 -3.290 .001 
Benefit Rx Drugs Yes No 
183 
191 
180.66 
194.05 -1.249 .211 
*Šidák Cutoff=0.017 
 
 
A subsequent Kruskal-Wallis One –Way Analysis of Variance (see Table 9) performed to 
test for differences between three groups separated by severity levels of side effects 
(mild, moderate, and severe) with the same independent variables revealed statistical 
differences in perceived harm and perceived risk of prescription drugs.  
 
Table 9. Perception of RX Drugs in Those Taking either an Oral 
DM Drug or Insulin between Severity of Side Effects 
 Med Side 
Effects? N Mean Rank Χ2 p-value* 
Harm Rx Drugs 
Mild 
Moderate 
Severe 
80 
69 
33 
78.54 
96.39 
112.70 
11.382 .003 
Risk Rx Drugs 
Mild 
Moderate 
Severe 
80 
69 
33 
105.70 
84.98 
70.71 
12.278 .002 
Benefit Rx Drugs 
Mild 
Moderate 
Severe 
80 
69 
33 
99.91 
86.84 
80.86 
4.235 .120 
*Šidák Cutoff=0.017 
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Aim 2: Adherence to Diabetes Treatments 
Adherence to Diabetes Medications 
        Adherence to diabetes medications was measured using the Morisky Scale, and 
scored on a range of 0-8 with a higher score representing higher adherence.  Because 
some Morisky items specifically inquire about oral medication use, the sample was 
filtered to only include oral DM medication users prior to analyzing the Morisky scale.  
The subjects recorded scores ranging from a minimum of 1.25 to a maximum of 8 with a 
mean of 6.34 (SD=1.55) and a median of 7.  After segmenting scores into adherence 
categories 34% of respondents had low adherence (0-5.9), 40.1% had medium adherence 
6-7.9), and 25.9% had high adherence (8).  The eight items of the Morisky scale had a 
Cronbach’s alpha of 0.6.  All 282 respondents who indicated current oral DM medication 
use completed the Morisky items. 
Adherence to Exercise 
     Adherence to exercise was measured using two questions found in the Summary of 
Diabetes Self-Care Activities (SDSCA).  The respondents’ minimum number of days 
participating in a specific exercise session for at least 30 minutes ranged from 0 days to a 
maximum of 7 days, with a mean of 2.78 (SD=2.18) days.  Nearly 1 out of 5 respondents 
(18.3%) indicated that they had not participated in any exercise in the previous 7 days, 
while nearly a similar percentage (22.3%) exercised at least 5 of the previous 7 days.  The 
exercise questions found in the SDSCA had a Cronbach’s alpha of 0.837.   
Adherence to Diet 
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     Adherence to diet was measured using 4 questions found in the SDSCA (Exhibit X). 
For the general diet questions respondents reported a minimum of 0 days and a maximum 
of 7 days, with a mean of 4.55 (SD=1.83) days.  Almost a quarter of subjects (22.7%) 
indicated that they followed a healthy eating plan 3 or less days per week.  The 
Cronbach’s alpha for the General Diet questions was 0.923. 
     Adherence to specific diet had two questions that asked about fruit and vegetable 
consumption and high-fat food consumption over the previous 7 days.  The specific diet 
question regarding high-fat foods was reverse-coded prior to analysis.  For the specific 
diet questions the respondents reported a minimum of 0 days with a maximum of 7 days 
and a mean of 3.83 (SD=1.56) days.  The Cronbach’s alpha for the Specific Diet 
questions was 0.269. 
Adherence to Foot Care 
     Adherence to foot care was measured using two questions found in the SDSCA that 
ask about checking feet and inspecting the inside of shoes.  The respondents reported a 
minimum of 0 and a maximum of 7 days with a mean of 3.12 (SD=2.32) days and a 
median of 3.5 days.  The Cronbach’s alpha for the foot care questions was 0.646. 
Adherence to Self-Monitoring of Blood Glucose 
     Adherence to blood glucose monitoring was measured using two questions found in 
the SDSCA.  The respondents reported a minimum of 0 and a maximum of 7 days with a 
mean of 3.90 (SD=2.73) days and a median of 4 days.  More than 1 in 4 respondents 
(27.8%) tested their blood glucose on a daily basis, while 18.9% indicated that they did 
not test once during the previous 7 days.  The Cronbach’s alpha for the two blood glucose 
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monitoring questions was 0.807.   
Cigarette Smoking 
     The SDSCA only asks about tobacco use in the form of cigarette smoking.  A majority 
of individuals (88.7%) had not smoked a cigarette in the previous 7 days, while 42 
individuals (11%) had at least one puff of a cigarette in the previous 7 days.  Of those that 
indicated cigarette usage, the minimum number of cigarettes smoked per day was 0 with 
a maximum of 30 and a mean of 9.76 (SD=7.44).     
 
Aim 3: Relationship between Risk Perception and 
Adherence to Diabetes Self-Care Behaviors 
          Separate regression models were created for adherence to medications, exercise, 
diet, and self-monitoring of blood glucose by using the Morisky scale for medication 
adherence and the relevant subscales in the SDSCA for the remaining dependent 
variables. Prior to analysis, the dependent variables for the separate models and the 
various independent variables (e.g. sociodemographic factors, threat, diabetes 
empowerment, and risk perception variables) were examined through IBM SPSS to check 
for assumptions of multivariate regression analysis, which include linearity of the 
relationship between the residuals of the independent with the dependent variables, no 
multicollinearity, homoscedasticity, and normality (Tabachnick & Fidell, 2007). 
     It was determined that a majority of variables had issues with skewness and kurtosis 
(generally platy-kurtic).  Additional evaluation using bivariate correlation matrices found 
some small, but significant correlations between dependent and independent variables, 
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but many relationships were non-linear.  To adhere to assumptions for normality, 
linearity, and homoscedasticity many of the independent and dependent variables were 
transformed using inverse, square root, or log transformations.  Subsequent bivariate 
correlation matrices and Kolmogorov-Smirnov tests were then used to determine 
adherence to multivariate regression assumptions.  Results of this evaluation led to the 
determination that meeting assumptions for multivariate linear regression was not 
feasible, and to proceed with binomial logistic regression, which allows for non-
normality and non-linearity of data (Tabachnick & Fidell, 2013). 
     Expected frequencies of the independent variables were checked to ensure variables 
had no more than 20% of cells with less than 5 values, which caused the variable 
“education” to be transformed to “college educated” (0=no, 1=yes), and “relationship 
status” to be transformed to “married” (also included “committed relationship”; 0=no, 
1=yes).  “History of DM side effects” had yes, no, and unsure as possible responses, 
which was changed to a dichotomous variable (no=0, yes and unsure=1). 
     Due to the large number of control variables Pearson χ2 test for association was 
utilized to narrow down possible nominal and ordinal controls, while the Pearson’s cross-
product-moment correlation coefficient was used to narrow down interval and ratio-level 
control. Independent variables with correlation coefficients of at least p<0.1 with respect 
to dependent variables were used in the respective models.  See Table 10 for a list of 
control variables. 
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Table 10.  Possible Control Variables in Logistic Regression Models 
Variable Name Variable Labels 
Age Age  
Income Income  
Threat Scale Threat  
Diabetes 
Empowerment 
Scale 
DES 
 
Time since T2DM 
Diagnosis DMDuration 
 
Gender Gender Female=0, Male=1 
Education EduCat Did not graduate college=0, College graduate=1 
History of T2DM 
medication side 
effects 
DMSideEffects No=0, Yes/Unsure=1 
Relationship Married No=0, Yes=1 
Saw T2DM 
Educator DMEducator No=0, Yes=1 
 
Medication Adherence Logistic Regression 
     Because the Morisky scale contains items that specifically inquire about oral 
medication use, only respondents who indicated current use of prescription oral diabetes 
medications were included in this analysis (n= 282).  The Morisky scale was transformed 
into two dichotomous groups: Morisky score 0-5.9 (0=nonadherent) and 6-8 
(1=adherent), which was used as the dependent variable in the logistic regression 
analysis.  
     See Table 11 for the correlations between respondents who were adherent/not 
adherent to medications and control variables.  Results from the correlation indicated that 
age, threat, and the Diabetes Empowerment Scale (DES) would control for the 
relationship between adherence/nonadherence to medications and risk perception.  
Correlation tests failed to find significance between Morisky adherent/nonadherent and 
harm, benefit; and risk perception variables of “Rx Drugs” and “Oral DM Drugs.” Thus, 
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only “Risk Oral DM Drugs” was used in the logistic regression analysis.   
Table 11. Correlations between Medication Adherence and Control 
Variables 
Variable 
Level of 
Measurement Pearson’s r or χ2  p-value* 
Age Scale r .276 .000 
Income Scale r -.042 .262 
Threat Scale r -.174 .004 
DES Scale r .195 .001 
DM Duration Scale r .045 .461 
Gender Nominal χ2 .586 .444 
Education Nominal χ2 .273 .602 
DMSideEffects Nominal χ2 1.367 .242 
Married Nominal χ2 .004 .952 
Saw DM 
Educator Nominal χ
2 .000 1.000 
* Correlation coefficients of at least p<0.1 were used in the respective model. 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; DM 
Duration=Years since T2DM diagnosis; Education= College graduate(1); 
DMSideEffects=Side effects attributed to T2DM medications in last 5 years; Saw 
DM Educator=Previously visited with Certified Diabetes Educator 
 
          A logistic regression model was estimated using the enter method to explore the 
relationship between medication adherence and risk perception of oral T2DM 
medications.  The final model is reported in Table 12.  The base model (constant) 
correctly predicted 65.3% of cases, while the full model correctly predicted 69.7% of 
cases, indicating improvement over the base model.  The Omnibus Test of Model 
Coefficients “goodness of fit” (χ2=32.811, df=4, p=.000) also indicates improvement of 
the full model over the base model (Burns & Burns, 2008).  The Hosmer and Lemeshow 
Test   (χ2=7.776, df=8, p=.456) indicates that the full model is a good fit (Tabachnick & 
Fidell, 2013).  The final model, as depicted in Table 12, is Logit (MoriskyAdherence)= 
1.050 (Age) + 1.824 (DES).  
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Table 12. 
Logistic Regression to Measure the Association between Medication Adherence 
and Risk Perception of Oral T2DM Drugs. 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Age .049 .013 13.433 1 0.000 1.050 1.023 1.078 
Threat -.058 .034 2.961 1 0.085 0.944 0.884 1.008 
DES 0.601 0.249 5.831 1 0.016 1.824 1.120 2.972 
RP_OralDMDrugs -0.013 0.073 0.032 1 0.858 0.987 0.856 1.138 
Constant -3.569 1.503 5.639 1 0.018 0.028   
N=274 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; 
RP_OralDMDrugs=Risk Perception of Oral DM Drugs 
 
 The final model revealed a significant correlation between age and adherence to 
diabetes treatments when controlling for threat, DES, and risk perception of oral DM 
drugs.  Specifically, older patients with T2DM were more likely to be adherent to their 
diabetes medications than younger patients.  A significant correlation was also found 
between the DES and medication adherence when controlling for threat, age, and risk 
perception of oral DM.  Specifically, respondents who scored a 5 on the DES were nearly 
7.3 times more likely to be adherent to diabetes medications than those who scored a 1 on 
the DES. Risk Perception of Oral T2DM medications was not significantly correlated 
with medication adherence (χ2=0.032, p=0.858), as it was not a useful predictor of 
adherence to medications in the logistic regression model.   
Exercise Adherence Logistic Regression 
     To create two dichotomous groups from the exercise subscale of the Summary of 
Diabetes Self-Care Activities it was decided to transform SDSCA Exercise into those that 
exercise 5 or more days per week (1=exercise adherent) and those that exercise less than 
5 days per week (0=exercise nonadherent).  The decision to dichotomize the exercise 
   53 
 
subscale in this manner was based on the “Standards of Medical Care in Diabetes—
2013” by the American Diabetes Association (ADA, 2013), and this dichotomous 
variable was used as the dependent variable in the logistic regression analysis. 
     See Table 13 for the correlations between respondents who were adherent/not 
adherent to exercise and control variables.  Because only those independent variables that 
had correlation coefficient p-values of less then or equal to 0.1 between respondents who 
were adherent/not adherent to exercise and their perceptions of harm, benefit, and risk 
perception of moderate intensity exercise, it was determined to use benefit (r=.088, 
p=.092) and risk (r=.102 , p=.048) perception of moderate intensity exercise as 
independent variables in separate logistic regression analyses.  
Table 13. Correlations between Exercise Adherence and Control 
Variables 
Variable 
Level of 
Measurement 
 
Test 
Statistic r or χ2 (df) p-value* 
Age Scale r 0.011 0.831 
Income Scale r 0.189 0.000 
Threat Scale r -0.057 0.283 
DES Scale r 0.183 0.000 
DM Duration Scale r -0.083 0.113 
Gender Nominal χ2 5.596(1) 0.018 
Education Nominal χ2 2.741(1) 0.098 
Married Nominal χ2 4.103(1) 0.043 
Saw DM 
Educator Nominal χ
2 1.100(1) 0.294 
* Correlation coefficients of at least p<0.1 were used in the respective model. 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; DM Duration=Years since 
T2DM diagnosis; Education= College graduate (1); Saw DM Educator=Previously visited with 
Certified Diabetes Educator 
 
A logistic regression model was estimated using the enter method to explore the 
relationship between exercise adherence and risk perception of moderate intensity 
exercise.  The final model is presented in Table 14.  The base model (constant) correctly 
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predicted 77.8% of cases, while the full model correctly predicted 79.8% of cases, which 
indicates an improvement over the base model.  The Omnibus Test of Model Coefficients 
“goodness of fit” (χ2=37.302, df=6, p=0.000) also indicates the improvement of the full 
model of the base model.  The Hosmer and Lemeshow Test   (χ2=13.292, df=8, p=0.102) 
indicates that the full model is a good fit.  The final model, as depicted in Table 14, is 
Logit (Exercise)= 1.084 (Income) + 2.953 (DES).  
Table 14. Logistic Regression to Measure the Association between Exercise 
Adherence and Risk Perception of Moderate Intensity Exercise 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Married (1) -0.399 0.356 1.252 1 0.263 0.671 0.334 1.349 
Education (1) -0.269 0.290 0.859 1 0.354 0.764 0.433 1.349 
Gender (1) -0.463 0.275 2.834 1 0.092 0.629 0.367 1.079 
Income 0.081 0.038 4.584 1 0.032 1.084 1.007 1.167 
DES 1.083 0.275 15.556 1 0.000 2.953 1.724 5.057 
RP_MIE 0.033 0.068 0.241 1 0.624 1.034 0.905 1.182 
Constant -6.025 1.318 20.886 1 0.000 0.002   
N=356 
DES=Diabetes Empowerment Scale;  
RP_MIE=Risk Perception of Moderate Intensity Exercise 
 
The final model revealed a significant correlation between household income and 
adherence to exercise when controlling for marriage status, education, gender, DES, and 
risk perception of moderate intensity exercise.  Specifically, patients with T2DM who 
have a higher household income were more likely to exercise 5 or more days per week.  
The logistic regression model suggests that those who make between $140,000 and 
$149,999 are 15.176 times more likely to exercise 5 or more times per week compared to 
those than make less than $10,000 per year. Additionally, the final model revealed a 
significant correlation between the DES and adherence to exercise when controlling for 
marriage status, education, gender, income, and risk perception of moderate intensity 
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exercise.  Those who scored a 5 on the Diabetes Empowerment Scale were 11.8 times 
more likely to be adherent to exercise recommendations compared to those who scored a 
1 on the DES in the final model.  Risk perception of moderate intensity exercise 
(χ2=0.241, p=0.624) was not significantly correlated with adherence to exercise.  The 
addition of benefit perception of moderate intensity exercise (in place of risk perception 
of moderate intensity exercise) did not improve the overall model and was not 
significantly correlated with adherence to exercise recommendations (χ2=0.126, 
p=0.723).   
Self-Monitoring Blood Glucose Adherence Logistic Regression 
     To create two dichotomous groups from the self-monitoring blood glucose (SMBG) 
subscale of the Summary of Diabetes Self-Care Activities it was decided to transform 
SDSCA Blood Glucose into  respondents who scored a 4 or greater (1=SMBG adherent) 
and respondents who scored less than 4 on the SMBG subscale (0=SMBG nonadherent), 
which was used as the dependent variable in the logistic regression analysis.  The 
decision to dichotomize the SMBG subscale in this manner was based on the median 
value of the subscale (median=4) in the study sample.  
     See Table 15 for the correlations between control variables and respondents scoring at 
or above the median and those scoring below the median of the blood glucose subscale of 
the SDSCA.  Because of the respective p-values of the correlation coefficients between 
respondents who were above/below median of blood glucose subscale of SDSCA and 
their perceptions of harm, benefit, and risk of self-monitoring of blood glucose, it was 
determined to use benefit (r=0.167, p=0.001) and risk (r=0.124 , p=0.017) perception of 
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SMBG as independent variables in separate logistic regression analyses.  
Table 15.  Correlations between SMBG Adherence and Control 
Variables 
Variable 
Level of 
Measurement 
 Test 
Statistic r or χ2 (df) p-value* 
Age Scale r 0.111 0.035 
Income Scale r -0.036 0.500 
Threat Scale r 0.051 0.330 
DES Scale r 0.088 0.095 
DM Duration Scale r 0.106 0.043 
Gender Nominal χ2 0.205(1) 0.651 
Education Nominal χ2 7.988(1) 0.005 
Married Nominal χ2 1.329(1) 0.249 
Saw DM 
Educator Nominal χ
2 3.704(1) 0.054 
* Correlation coefficients of at least p<0.1 were used in the respective model. 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; DM Duration=Years since 
T2DM diagnosis; Education= College graduate(1); Saw DM Educator=Previously visited with 
Certified Diabetes Educator 
 
          A logistic regression model was estimated using the enter method to explore the 
relationship between SMBG adherence and risk perception of SMBG.  The final model is 
reported in Table 16.  The base model (constant) correctly predicted 51.2% of cases, 
while the full model correctly predicted 62.1% of cases, which indicates an improvement 
over the base model.  The Omnibus Test of Model Coefficients “goodness of fit” 
(χ2=25.021, df=6, p=0.000) also indicates the improvement of the full model of the base 
model.  The Hosmer and Lemeshow Test   (χ2=13.217, df=8, p=0.105) indicates that the 
full model is a good fit.  The final model, as depicted in Table 16, is Logit (SMBG)= 
1.955 (Education) + 1.182 (RP_SMBG).  
 The final model revealed a significant correlation between college graduation and 
adherence to self-monitoring of blood glucose when controlling for age, DES, duration of 
T2DM, history of a visit with a certified diabetes educator, and risk perception of SMBG.  
Specifically, patients with T2DM who have graduated from college were nearly twice as 
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likely (1.955 times) to score a 4 or greater on the self-monitor blood glucose subscale of 
the SDSCA in the final model.   
Table 16.  Logistic Regression to Measure the Association between SMBG 
Adherence and Risk Perception of SMBG 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Age 0.012 0.010 1.419 1 0.234 1.012 0.992 1.033 
DES 0.181 0.193 0.879 1 0.349 1.199 0.821 1.751 
DMDuration 0.025 0.014 3.165 1 0.075 1.025 0.997 1.054 
DMEducator(1) -0.324 0.283 1.313 1 0.252 0.723 0.416 1.259 
Education 0.670 0.219 9.330 1 0.002 1.955 1.217 3.005 
RP_SMBG 0.167 0.076 4.886 1 0.027 1.182 1.019 1.371 
Constant -3.889 1.245 9.762 1 0.002 0.020   
N=367 
DES=Diabetes Empowerment Scale; DMDuration= Years since T2DM diagnosis; Saw DM 
Educator=Previously visited with Certified Diabetes Educator;  
RP_SMBG=Risk Perception of Self-Monitoring of Blood Glucose 
 
 
The final model also revealed a significant correlation between risk perception of SMBG 
and adherence to SMBG when controlling for age, DES, duration of T2DM, education, 
and history of a visit with a certified diabetes educator.  Specifically, each increment of 
increase in risk perception score increased the likelihood of scoring at least a 4 on the 
SMBG subscale of the SDSCA by 1.182 times; thus, respondents scoring a 13 were 8.274 
times more likely than those scoring a 6 (minimum score in this study sample) to score at 
least a 4 on the SMBG subscale of the SDSCA. 
     A separate regression model was estimated to explore the relationship between SMBG 
adherence and benefit perception of SMBG.  The final model is reported in Table 17.  
The base model (constant) correctly predicted 50.9% of cases, while the full model 
correctly reported 62.9% of cases, which indicates an improvement over the base model.  
The Omnibus Test of Model Coefficients “goodness of fit” (χ2=30.207, df=6, p=0.000) 
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also indicates the improvement of the full model of the base model.  The Hosmer and 
Lemeshow Test   (χ2=8.405, df=8, p=0.395) indicates that the full model is a good fit.  
The final model, as depicted in Table 17, is Logit (SMBG)= 1.868 (Education) + 1.404 
(B_SMBG). 
Table 17. 
Logistic Regression to Measure the Association between SMBG Adherence and 
Benefit Perception of SMBG 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Age 0.014 0.010 1.864 1 0.172 1.014 0.994 1.035 
DES 0.152 0.193 0.621 1 0.431 1.164 0.797 1.701 
DMDuration 0.027 0.014 3.750 1 0.053 1.028 1.000 1.057 
DMEducator(1) -0.296 0.284 1.090 1 0.296 0.744 0.427 1.297 
Education 0.625 0.220 8.072 1 0.004 1.868 1.214 2.875 
B_SMBG 0.339 0.117 8.381 1 0.004 1.404 1.116 1.767 
Constant -4.091 1.128 13.161 1 0.000 0.017   
N=367 
DES=Diabetes Empowerment Scale; DMDuration=Years since T2DM diagnosis; Saw DM 
Educator=Previously visited with Certified Diabetes Educator Education=College graduate 
(1); B_SMBG=Benefit Perception of Self-Monitoring of Blood Glucose 
 
          Similar to the previous model that instead included risk perception of SMBG as a 
predictor, this model again suggests a significant positive correlation between college 
education and adherence to SMBG when controlling for controlling for age, DES, 
duration of T2DM, history of a visit with a certified diabetes educator, and benefit 
perception of SMBG.  Specifically, college-educated individuals were nearly twice as 
likely (1.868 times) to score at or above the median on the blood glucose subscale of the 
SDSCA in this model.  Benefit perception of SMBG was also found to be significantly 
positively correlated with adherence to SMBG.  Specifically, each increment of increase 
in benefit perception of SMBG score increased the likelihood of scoring at least a 4 on 
the SMBG subscale of the SDSCA by 1.404 times; thus, using this model respondents 
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scoring a 7 were 8.424 times more likely than those scoring a 1 to score 4 or greater on 
the SMBG subscale of the SDSCA. 
Diet Adherence Logistic Regression 
     To create two dichotomous groups from the general diet subscale of the Summary of 
Diabetes Self-Care Activities it was decided to transform SDSCA general diet into 
respondents who scored a 5 or greater (1=Diet Adherent) and those who scored less than 
4 on the general diet subscale (0=Diet nonadherent), which was used as the dependent 
variable in the following logistic regression analysis.  The decision to dichotomize the 
SMBG subscale in this manner was based on the median value of the subscale 
(median=5).   
     See Table 18 for the correlations between control variables and respondents scoring at 
or above the median and those scoring below the median of the general diet subscale of 
the SDSCA.  Because of the respective p-values of the correlation coefficients between 
respondents who were above/below median of the general diet subscale of the SDSCA 
and their perceptions of harm, benefit, and risk of both high sugar foods and high fat 
foods, it was determined to use harm (r=-0.097, p=0.061) and risk (r=0.102 , p=0.050) of 
high fat foods as independent variables in separate logistic regression analyses.  
 
     A logistic regression model was estimated using the enter method to explore the 
relationship between diet adherence and risk perception of SMBG.  The final model is 
reported in Table 19. The base model (constant) correctly predicted 53.9% of cases, while 
the full model correctly predicted 64.3% of cases, which indicates an improvement over 
the base model.  The Omnibus Test of Model Coefficients “goodness of fit” (χ2=35.664, 
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df=5, p=0.000) also indicates the improvement of the full model of the base model.  The 
Hosmer and Lemeshow Test   (χ2=1.505, df=8, p=0.993) indicates that the full model is a 
good fit.  The final model, as depicted in Table 19, is Logit (GeneralDiet)= 2.303 (DES) 
+ 1.143 (RP_HFF). 
Table 18.  Correlations between General Diet Adherence and Control 
Variables 
Variable 
Level of 
Measurement 
 Test 
Statistic r or χ2 (df) p-value* 
Age Scale r 0.135 0.010 
Income Scale r 0.049 0.355 
Threat Scale r -0.092 0.080 
DES Scale r 0.220 0.000 
DM Duration Scale r -0.051 0.335 
Gender Nominal χ2 0.003(1) 0.960 
Education Nominal χ2 0.965(1) 0.326 
Married Nominal χ2 3.123(1) 0.077 
Saw DM 
Educator Nominal χ
2 1.724(1) .189 
* Correlation coefficients of at least p<0.1 were used in the respective model. 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; DM 
Duration=Years since T2DM diagnosis; Education= College graduate(1); 
Saw DM Educator=Previously visited with Certified Diabetes Educator  
  
Table 19. 
Logistic Regression to Measure the Association between General Diet Adherence 
and Risk Perception of High Fat Foods 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Married(1) -0.453 0.249 3.314 1 0.069 0.635 0.390 1.035 
Age 0.019 0.010 3.488 1 0.062 1.019 0.999 1.039 
Threat -0.009 0.025 0.121 1 0.728 0.991 0.943 1.042 
DES 0.834 0.212 15.497 1 0.000 2.303 1.520 3.490 
RP_HFF 0.134 0.051 6.849 1 0.009 1.143 1.034 1.263 
Constant -4.354 1.147 14.401 1 0.000 0.013   
N=373 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; RP_HFF=Risk Perception of 
High Fat Foods 
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          The final model revealed a significantly positive correlation between adherence to 
general diet recommendations for healthy eating and DES when controlling for age, 
threat, and the risk perception of high fat foods.  Respondents who scored a 5 on the DES 
were 9.212 times more likely to follow the healthy diet recommendations than those who 
score a 1 in this model.  Risk perception of high fat foods was also significantly 
positively correlated with adherence to general diet recommendations for health eating in 
the final model when controlling for age, threat, and the DES.  Specifically, in this model 
respondents who scored a 13 on RP_HFF were 13.716 times more likely to follow 
healthy diet recommendations than those who scored a 1. 
     The logistic regression model with the same predictors was also computed using harm 
perception and benefit perception of high fat foods as predictors (in separate models).  
Benefit perception was not a significant predictor (Exp(B)=1.167, p=0.074), while harm 
perception (Exp(b)=.807, p=0.011) was a significant predictor of adherence to a healthy 
diet in the logistic regression model; thus, paradoxically, respondents who had a higher 
perception of harm for high fat foods were less likely to adhere to a healthy diet.  
Smoking Logistic Regression 
     Study participants were asked if they had smoked (at least one puff) of a cigarette in 
the past 7 days.  This item was coded as smokers (1=yes) and nonsmokers (0=no) and 
used as the dependent variable in the following logistic regression analysis.  
     See Table 20 for the correlations between control variables and respondents self-
identifying as either smokers or nonsmokers.  Because of the respective p-values of the 
correlation coefficients between respondents who are smokers vs. nonsmokers and their 
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respective perceptions of harm, benefit, and risk of cigarette smoking, it was determined 
to use harm (r=-0.175, p=0.001), benefit (r=-0.196, p=0.000) and risk (r=0.246 , 
p=0.000) perception as independent variables in the logistic regression analysis. 
Table 20. Correlations between Cigarette Smoking Status and Control 
Variables 
Variable 
Level of 
Measurement 
 
Test 
Statistic r or χ2 (df) p-value* 
Age Scale r -0.128 0.015 
Income Scale r 0.005 0.927 
Threat Scale r 0.017 0.774 
DES Scale r -0.082 0.116 
DM Duration Scale r -0.089 0.088 
Gender Nominal χ2 4.691(1) 0.030 
Education Nominal χ2 0.207(1) 0.649 
Married Nominal χ2 0.524(1) 0.469 
Saw DM 
Educator Nominal χ
2 0.220(1) 0.639 
* Correlation coefficients of at least p<0.1 were used in the respective model. 
Threat=Threat of diabetes; DES=Diabetes Empowerment Scale; DM 
Duration=Years since T2DM diagnosis; Education= College graduate (1); Saw DM 
Educator=Previously visited with Certified Diabetes Educator 
 
     A logistic regression model was estimated using the enter method to explore the 
relationship between adherence to recommendations to refrain from cigarette smoking 
and perceptions of cigarette smoking.  The final model is reported in Table 21.  The base 
model (constant) correctly predicted 88.7% of cases, while the full model correctly 
predicted 88.4%, which indicates that the full model is not an improvement over the base 
model.  The Omnibus Test of Model Coefficients “goodness of fit” (χ2=25.054, df=4, 
p=0.000) indicates an improvement of the full model compared to the base model.  The 
Hosmer and Lemeshow Test (χ2=5.350, df=8, p=0.720) indicates that the full model is a 
good fit.  The final model, as depicted in Table 21, is Logit (Smoking)= 1.511 (RP_CS). 
 
   63 
 
 
Table 21.  Logistic Regression to Measure the Association between Smoking and 
Risk Perception of Cigarette Smoking 
                  95% CI for Exp(B) 
 B S.E. Wald Df Sig. Exp(B) Lower Upper 
Age -0.027 0.016 2.834 1 0.092 0.974 0.944 1.004 
DMDuration -0.025 0.026 0.936 1 0.333 0.976 0.928 1.026 
Gender (1) 0.552 0.358 2.374 1 0.123 1.737 0.860 3.508 
RP_CS 0.413 0.099 17.341 1 0.000 1.511 1.244 1.835 
Constant -1.362 0.949 2.060 1 0.151 0.256   
N=371 
DMDuration=Years since T2DM diagnosis; RP_CS=Risk Perception of Cigarette Smoking 
 
          As indicated, the model suggests a significant positive correlation between risk 
perception of cigarette smoking and the likelihood that the individual is a cigarette 
smoker.  Specifically, in this model an individual who scored an 8 on the Risk Perception 
of Cigarette Smoking scale was 10.577 times more likely to be a smoker than nonsmoker.  
Similarly, in separate models, the more harm (exp(B)=0.621, p=0.001) one perceived 
towards cigarette smoking use was a significant predictor of abstaining from cigarette 
smoking, and the more benefit (Exp(B)=1.551, p=0.003) one perceived towards smoking 
was a significant predictor of being a smoker.  
Summary 
     Results suggest that respondents who have T2DM perceive medications as having an 
overall net benefit.  Of those medications studied, most were deemed to be of similar 
benefit and harm.  Differences were also seen in perceptions of oral DM drugs between 
users and nonusers of diabetes medications.  Furthermore, differences in perception with 
several of the studied variables were seen between men and women. Risk perception 
differences were also seen between respondents with or without a history of medication 
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side effects , and differences in risk perception were seen between groups segmented by 
severity of side effects experienced. 
     Adherence to recommended diabetes-related treatments varied among study 
respondents.  Harm, benefit, and risk perception variables had varying effects on logistic 
regression models measuring association with relevant adherence measures.  While 
perceptions of prescription medications and oral diabetes medications were not 
significantly correlated with medication adherence, perception of SMBG and high fat 
foods had significant positive correlations with blood glucose monitoring and general 
diet, respectively.     
 
CHAPTER 5: Discussion 
     A gap in knowledge exists in the understanding of the influence of risk perception on 
adherence to treatments related to diabetes.  The purpose of this explanatory, descriptive 
study was to address the perceptions of risk and its relationship with self-care adherence 
in those with T2DM.  This discussion is structured to address the major findings found 
within the results of the three aims of this study, which were the following: 
Aim 1: To quantitatively describe risk perception in persons with T2DM.  
Aim 2: To describe levels of adherence for diabetes self-care behaviors, including 
medication use, diet, exercise, foot care, smoking, and self-monitoring of blood 
glucose.  
 Aim 3: To examine the relationship between risk perception and adherence to 
 diabetes self-care behaviors, including medication use, diet, exercise, foot care, 
 smoking, and self-monitoring of blood glucose. 
   65 
 
Major Findings 
Risk Perception in Persons with T2DM 
     The results of this study were consistent with previous risk perception research (Slovic 
et al, 2007; Slovic et al., 1991; Slovic et al., 1987).  In this study prescription medications 
were considered to be high in perceived benefit and low in perceived harm.  As seen in 
Figure 7, most prescription medications used for diabetes and its related comorbid 
conditions, such as insulin, oral diabetes drugs, aspirin, and drugs for hypertension and 
cholesterol, are all grouped closely together.  These products were markedly different 
from other chemicals respondents were asked to risk-rate, including pesticides, alcohol, 
and food additives.  While respondents rated most medications similarly, diet drugs were 
perceived to offer similar levels of harm and benefit as alcoholic beverages. 
      Although not tested for statistical significance, insulin was perceived to have a 
higher potential for harm compared to oral diabetes drugs, while also being perceived to 
have more potential for benefit; however, risk perception of insulin and oral diabetes 
drugs (the difference between perceived benefit and perceived harm) was nearly 
identical.    
 Earlier research identified differences in risk perception between men and women 
(Slovic et al., 2007).  Consistent with this earlier research, findings in the present study 
also revealed a several differences between male and female respondents.  Women 
perceived higher harm for both nuclear power and air travel, which is similar previous 
research (Slovic et al., 2007).  Of particular importance to patients with T2DM, women 
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perceived a higher benefit for oral diabetes drugs, drugs for neuropathy, and self-
monitoring of blood glucose.  
 Results from this survey were similar to those results from a national survey 
conducted previously in the United States.  Figure 7 was compared to a similar plot of 
benefit and harm perceptions found in Slovic et al. (2007).   
Figure 11. Plot of Mean Benefit and Harm Perception by Respondents Who Have 
Type 2 Diabetes Compared with Respondents from a National Survey Not 
Identifying with a Particular Disease State 
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It is of particular importance to note that previous research did not focus on 
subjects who were diagnosed with a particular disease; rather, the research explored if 
risk perceptions differed between those who took medications versus those who 
completely abstained from medication use for their respective conditions. Mean rankings 
of the individual risk items from the previous study were not available; thus, comparing 
risk perceptions between the two studies was only done through visual inspection of the 
harm and benefit plots.   
      All of the products located in or near the “Low Benefit-High Harm” quadrant, 
which included cigarette smoking, high fat foods, alcoholic beverages, diet drugs and 
sleeping pills, were in similar positions in their respective plots.  No great deviations 
between the two plots were easily visualized; however, drugs for anxiety and drugs for 
depression appear to have been deemed less harmful and more beneficial in the current 
study of patients with diabetes compared to the previous study.  This is of particular 
significance, as depression (especially in those with T2DM) has been acknowledged as a 
modifiable risk factor for medication nonadherence (Gellad et al., 2009).  
Several items moved from their respective “quadrants” between the prior study 
and the current study.  Please see Table 22 for a list of those products were found in 
different quadrants in Figure 11. Of the 10 products that changed, 3 were medication 
related (drugs for anxiety, drugs for depression, and sleeping pills). 
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Table 22. Items Switching Quadrants as Seen in Figure 11 
High	  to	  Low	  	  
Harm	  
Low	  to	  High	  	  
Harm	  
High	  to	  Low	  
Benefit	  
Low	  to	  High	  
Benefit	  Automobiles Food	  Additives Household	  Cleaners Sleeping	  Pills Drugs	  for	  Anxiety Genetically	  Modified	  Foods Nuclear	  Power	  Plants Coffee Drugs	  for	  Depression  Pesticides  
 
It is not possible to deliniate the reasons for the differences between the 
perceptions of depression and anxiety medications in this study’s sample versus that from 
Slovic et al. (2007).  It could simply be a regional difference (upper Midwest of the 
United States compared to a national sample), a true difference in how patients with 
T2DM perceive these medications compared to the general population, or perhaps a 
decrease in the stigma and and increase in the acceptance of a biological basis for mental 
illness.  Additionally, it has been noted that pharmaceutical companies have spent 
tremendous sums of money on direct-to-consumer advertising with the goal of improving 
perceptions of drugs for mental illness (Greenslit & Kaptchuk, 2012).  
Adherence to Treatments 
Roughly one-third (34%) of subjects were considered nonadherent to oral diabetes 
medications, consistent with previous research using the Morisky Medication Adherence 
Scale (Walker, et al., 2011), and similar to previous medication adherence studies 
(Garcia-Perez, Alvarez, Dilla, Gil-Guillen, & Orozco-Beltran, 2013).  As the Morisky 
Medication Adherence Scale is specific for oral medication use, it is unknown what 
adherence to insulin use was in this study sample.     
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      Patients in this study followed recommendations for exercise less than 3 days per 
week on average, while nearly 1 out of every 5 patients did not exercise at all in the 
previous 7 days.  Of all treatments examined in the current study, exercise had the lowest 
adherence rate.  Exercise is an important component of treating T2DM, as exercise is 
effective at naturally lowering blood glucose (Colberg, Sigal, Fernhall, Regensteiner, 
Blissmer, et al., 2010; Maiorana, O’Driscoll, Goodman, Taylor, & Green, 2002). The 
American Diabetes Association (ADA, 2015) recommends that patients get 30 minutes of 
continuous exercise at least 5 days a week.   
     Along with medications and exercise, a healthy diet is a cornerstone of a T2DM 
treatment regimen.  A healthy diet can greatly reduce the risk of diabetes and associated 
comorbidities (e.g., cardiovascular disease).   The sample in the current study reported 
following healthy eating recommendations an average of 4.55 days of the week, but over 
1 in 5 respondents followed a healthy diet less than 3 days per week, which is consistent 
with previous research (Carpenter, 2012).  
      Self-monitoring of blood glucose is a key method for patients to remain aware of 
their own diabetes care.  Nearly 1 in 5 individuals in this study had not tested blood 
glucose once in the previous 7 days, while half of the respondents tested at least 4 days in 
the past week.  Research suggests a relationship between SMBG frequency and lower 
A1C (Miller, Beck, Bergenstal, 2013).  It is unknown whether respondents were simply 
nonadherent to suggested SMBG frequency, whether their respective providers chose not 
to give targets for SMBG (providing less incentive for patients to self-test), or both. 
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        Most individuals in this study had not smoked a cigarette in the previous 7 days, 
while 11% had smoked a cigarette.  This is lower than the average adult smoking rate in 
the State of Minnesota (14.4%; Tobacco Use in Minnesota, 2014), and in the United 
States (17.8%; CDC, 2013).  It is not known whether individuals used other forms of 
tobacco (e.g., pipe, cigar, chewing, etc.)  While respondents had a lower smoking rate 
than the Minnesota average, the decades-long trend in dropping smoking rates has slowed 
or plateaued, and practitioners must remain vigilant in discussing cigarette smoking with 
patients (CDC, 2014).  
Relationship between Risk Perception and Adherence to T2DM Treatments 
Logistic regression was used to identify independent variables that had 
statistically significant correlations with the various adherence measures.  No clear 
pattern existed between the independent variables that were statistically correlated to the 
dependent variables, and significant relationships between harm, benefit, and risk 
perception variables with the adherence measures varied.  This finding highlights the 
difficulty clinicians face when attempting to modify patients’ behaviors, and reinforces 
the notion that behavior modification is time-intensive and must be patient-centric. 
The Diabetes Empowerment Scale, which measures self-efficacy, was 
significantly correlated with the Morisky Scale (medication adherence), exercise, and 
diet.  No other independent variable was significantly correlated with multiple adherence 
measures.  Age was significantly correlated with medication adherence; income was 
significantly correlated with exercise; and education was significantly correlated with 
self-monitoring of blood glucose (SMBG).  Because age was correlated with medication 
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adherence, clinicians should pay particular attention to medication adherence when 
speaking with younger patients.  Perhaps focusing on medication adherence when a 
patient is young will help form positive habits that will remain as patients grow older.  
Medication adherence barriers should be investigated that may be more pronounced in 
younger patients (e.g. lower income, jobs with poor health benefits, time constraints).  
Clinicians working with individuals with lower household incomes should focus on 
potential causes of exercise nonadherence.  If cost of exercise is described as a barrier by 
patients, then a clinician can focus on areas of the household budget that could be 
trimmed down (e.g. cigarettes, alcohol, unhealthy food choices) to accommodate the cost 
of exercise (e.g. running shoes or a gym membership).  Although formal education was 
correlated with SMBG, clinicians should continually focus on educating all patients about 
the importance of SMBG.      
 Risk perception of oral diabetes drugs was not significantly correlated with the 
Morisky (medication adherence) scale.  Likewise, risk perception of moderate intensity 
exercise was not correlated with exercise adherence.  
Cigarette smoking was significantly associated with harm of (negative 
correlation), benefit (positive correlation), and risk perception (negative correlation) of 
cigarette smoking.  However, because such a high percentage of respondents reported to 
be nonsmokers (88.7%), the constant-only logistic regression model correctly predicted 
more cases than the full model.  This suggests that the full model may not be useful in 
predicting smoking status, but the logistic regression was conducted to measure the 
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relationship between risk, harm, and benefit perception of smoking with smoking status 
with no intention of creating a model to use for future predictions of cigarette smoking.   
Risk and benefit perception of SMBG was significantly correlated with SMBG 
adherence.  Similarly, risk and harm perception of high fat foods was significantly 
correlated with general diet adherence.  Importantly, a decrease in perceived harm from 
high fat foods increased adherence to the general diet subscale of the SDSCA.  Benefit of 
high fat foods was not correlated nor was risk, harm, or benefit perception of high sugar 
foods correlated with adherence to a healthy diet.  It may seem contradictory that a 
decrease in harm perception of high fat foods would lead to improved adherence to a 
healthy diet; however, it could be hypothesized that those who understand the role of fats 
in a diet will follow an all-around healthier eating plan.   
Both risk and benefit perceptions of SMBG were significant predictors of the 
likelihood that an individual in this study would test blood glucose more than the median 
number of days reported by respondents.  Along with the previously mentioned 
differences in perception of blood glucose testing between men and women, it appears 
that this is a good area for enhanced discussion.  Awareness of blood glucose control 
could provide increased autonomy over one’s health and will provide feedback as to how 
other areas of self-care (i.e. medications, exercise, and diet) are lowering blood glucose.  
Knowing target blood glucose values and why reaching those targets are important may 
empower patients to control their diabetes. 
Perceived threat, as measured by the Perceived Threat subscale of the Cognitive 
Appraisal of Health Scale, did not appear to be significantly correlated to the various 
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studied adherence measures, which is in contrast to previously mentioned research 
(Carpenter, 2012).  Internal consistency with the scale was acceptable with a Cronbach’s 
alpha of 0.859; therefore, it is unclear whether perceived threat of T2DM truly does not 
influence one’s adherence to self-care treatments or if the scale used accurately measures 
the perceived threat concept in this population.  
Implications 
     Analysis of the results of this study suggest a potential link between risk perceptions 
and adherence to diabetes-related self-care treatments; however, when considering these 
associations, one should remember that this study was conducted in a small sample from  
one region, and the study is not a replication of previous research.  Thus, conclusions are 
not definitive and should not be used across the broader population of patients with 
T2DM.   
The respondents in this study had varying degrees of adherence to diabetes-
related treatments.  Adherence rates for the various self-care activities were similar to 
previously studied groups (Carpenter, 2012; Gonzalez, Safren, Cagliero, Wexler, 
Delahanty, Wittenberg, …, & Grant, 2007).  As such, practitioners and patients should 
continually focus on increasing the rates of adherence to the various activities.  The 
adherence scales used for this study, the SDSCA and MMAS-8, take patients little time to 
complete, yet yield excellent insight into self-care areas that might benefit from attention.  
Gaining insight behind adherence also allows the patient and practitioner to focus 
attention at the area(s) that might most increase adherence rates.  Each treatment 
recommendation, whether for medications, diet, or exercise, has multifactorial causes for 
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nonadherence, and adherence to one area does not imply adherence to another.  Thus, 
each treatment area should be independently assessed for adherence.  However, because 
most treatment areas in the current study saw relatively high rates of nonadherence (e.g. 1 
in 5 never self-monitored blood glucose and nearly 30% were nonadherent to 
medications), most patients would benefit from routine reminders about the importance 
of lifestyle modifications and medications. 
      The Diabetes Empowerment Scale had significant positive correlations with 
medication, exercise, and diet adherence. With the little time providers are afforded to 
educate patients, it would be best to focus on areas that have the most evidence-based 
support; focusing on increasing patient self-efficacy may be a productive way to improve 
multiple areas of self-care. 
      It is interesting to note that high fat and high sugar foods had nearly identical 
benefit and harm perceptions, and they also had risk perceptions that were viewed 
similarly to electronic cigarettes but were perceived to be more harmful than alcoholic 
beverages and diet drugs.  The sample in this study perceived the benefits and harms of 
high fat foods similarly to previous studies even as research suggests that evidence did 
not support decades-old dietary fat intake guidelines (Harcombe et al., 2015).  Because of 
the relationship between T2DM and carbohydrates, it is understandable that patients 
would view high sugar foods as harmful; however, viewing high fat foods as having 
equal possibility of harm compared to high sugar foods shows a possible failure in 
nutrition advice.  Excess carbohydrates are an indisputable cause of T2DM, and 
uncontrolled blood glucose is what leads to the untoward complications of the disease.  
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Much evidence has emerged that dietary fat and cholesterol is not as detrimental as once 
thought, and can even be cardio protective in those with T2DM (Hu, Cho, Rexrode, 
Albert, & Manson, 2003).  In fact, many of the diets often considered to lower risk of 
heart disease have higher fat content (e.g. Mediterranean; Estruch, Ros, Salas-Salvado, 
Covas, Corella, et al., 2013).  Furthering the need to focus on this area of education, 
recent research has pointed to high fat diets as producing more sustainable weight loss 
compared to high carbohydrate diets (Bazzano et al., 2014).  Health practitioners could 
consider discussing the positives and negatives of high fat compared with high sugar 
foods.  
Relative to all items included in the risk perception portion of this study, patients 
perceived moderate intensity exercise as the fifth least harmful and tenth most beneficial; 
however, perception of moderate intensity exercise was not significantly correlated with 
exercise adherence.  As was stated above, self-efficacy was significantly correlated with 
the likelihood to exercise.  Thus, empowering individuals to exercise should be a key 
component when discussing this issue with patients.  Exercise does not need to be costly, 
and although time cost can be expensive (especially for those needing to work multiple 
jobs), patients should be motivated to add physical activity throughout the day (e.g. 
parking farther away from work or taking the stairs instead of the elevator).  The 
American Diabetes Association recommends at least 150 minutes of exercise per week 
broken up into at least 30-minute segments with no more than two consecutive days off 
per week (ADA, 2015). Research suggests that breaking the 30 minutes into smaller time 
segments can still yield significant results (Bhammar, Angadi, & Gaesser, 2012).  So, all 
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amounts of exercise should be encouraged instead of creating an “If I can’t get in 30 
minutes, I might as well not even try” mentality.  The use of pedometers or journaling 
may also be of benefit to lessen discouragements if “results” are not achieved quickly 
enough.  Likewise, if subjective results are largely based on weight loss and physique, it 
is important to educate that no amount of exercise can compensate for an unhealthy, high 
calorie diet.  
Risk Perception 
Risk perception of diabetes medications does not appear to be significantly 
correlated with medication adherence in this sample, even though it has been previously 
connected to users and abstainers of medications (Slovic et al., 2007).  Factors leading to 
medication nonadherence have been linked to cost, regimen, and medication beliefs; 
however, in this study risk perception of oral diabetes drugs (medication belief) was not 
significantly correlated with medication adherence.  This is an instance where a 
“negative” result is as important as a positive correlation.  With the limited time and 
resources that practitioners can devote to individual patients, it is important that 
practitioners focus attention on the areas that will change behaviors and improve 
morbidity and mortality.  Thus, this research suggests that clinicians should spend a lot of 
limited face-to-face time with patients discussing potential harms and benefits of oral 
T2DM drugs, but should balance this discussion with other education topics that might 
aid in modifying self-care behaviors.   
It has been acknowledged in previous research that spouses play an important role 
in influencing their partners’ treatment adherence for chronic illnesses (Ell, 1996; 
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Revenson, 2003).  In the current study, women perceived more benefit than men from 
oral DM drugs and SMBG. Recognizing that women are more inclined to see the benefit 
from oral DM drugs and SMBG, it may be prudent to educate patients’ female partners 
with the goal of them discussing diabetes-related issues with male patients.  This could be 
of particular importance with SMBG, which was significantly positively correlated with 
likelihood to test blood glucose in this study.    
Limitations 
     This explanatory, descriptive study has several limitations that need to be 
acknowledged.  First, the study design was based on a self-selected sample of patients 
with T2DM who had received care at an Essentia Health facility at least once over the 
previous three years. All collected data was based on self-report and was not 
independently verified using a medical record. 
     The study was only delivered electronically to those patients that had email addresses 
on file.  It was impossible to know how many patients had actually read the request to 
participate in the study, and due to privacy constraints placed on the study by Essentia 
Health, survey emails were only sent once to each sampled participant.  Because it was 
completed online, it was also impossible to verify that the self-reported data was 
accurate.  Although guaranteeing the anonymity of respondents was a paramount 
consideration in this study, individuals invited to participate may still have been skeptical 
that they were being “tracked,” so either did not participate in the survey at all or 
answered less-than-truthfully.  Online surveys also preclude those who do not have email 
addresses on file or who do not have the computer skills required to navigate an online 
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survey.  The response rate (8.1%) was low.  A comparison of paper-based vs. online-
based survey response rates shows online response rates between 20%-47%, which were 
up to 35% lower than their respective paper-based surveys (Nulty, 2008).  Because of the 
low response rate, nonresponse bias must be considered, which is especially true 
considering the demographics of this sample do not mirror the general population.  
However, a low response rate does not automatically mean the results are 
unrepresentative of the broader population (Visser, Krosnick, Marquette, & Curtin, 
1996).    
     Multicollinearity of variables in the logistic regression analysis is a possible 
limitation, which can make interpreting significance tests of the individual predictors in 
the logistic regression models difficult to interpret. Additionally, the study did not control 
for confounding factors that may have influenced the dependent variables.  As 
acknowledged several times previously, causes of nonadherence are multifactorial and 
individualistic, and it was not feasible (or possible) to gather all possible independent 
variables that influence adherence to diabetes-related treatments. 
     As with any study using scales there are inherent issues with scale design that create 
limitations.  There is currently not a “best practice” for measuring medication adherence, 
and the Morisky Medication Adherence Scale is considered “gold standard” when using 
survey methodology, but the survey does not allow one to know if the subject actually 
used the medication as directed.  Similar issues were identified in the SDSCA.  For 
example, with the SMBG questions subjects were asked to indicate the number of days 
during the last week that they had tested blood sugar the number of times recommended 
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by a healthcare provider.  If a healthcare provider indicated zero times then the subject 
would be correct to mark “zero,” but this would then lower the mean response and 
indicate poor adherence to SMBG.   
Future Research 
      This study emphasizes the need for more research exploring the relationship 
between not only T2DM and risk perception, but also the relationship between risk 
perception and other disease states.  Of particular note is the perception this sample had 
of cancer chemotherapy, which is sometimes the best option for cancer treatment, but is 
also known for its horrendous side effects.  Alternatively, research could focus on the 
differences between perceptions of those with ailments that one can “feel” (e.g. 
migraines) versus “silent” conditions (e.g. hyperlipidemia). 
 As was noted earlier in this chapter, perception of high-fat foods was significantly 
correlated with eating an overall healthier diet.  With all of the inappropriate and 
misguided information swirling around the press regarding dietary fats, future research 
could explore patients’ understanding of healthy versus unhealthy diets, and how fats and 
carbohydrates contribute to diabetes and related comorbidities.  
 Future research could focus on matching providers’ risk profiles to those of their 
respective patients.  Perhaps patients who have harm and benefit perception of various 
treatment modalities that are similar to those of their respective providers will achieve 
better outcomes than those patients whose perceptions are not in alignment with their 
providers.  Similarly, research could investigate how providers’ risk perceptions 
influence clinical decisions and treatment recommendations. 
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     Studies focusing on adherence to treatments generally have inherent methodological 
issues with regards to measurement of adherence.  While the 8-item Morisky Medication 
Adherence Scale (MMAS-8) was used for this study, there is no gold standard, and 
measuring medication adherence using additional methods (e.g. percent of days covered, 
self-reported medication taking journal, vial cap that logs openings, etc.) might yield 
different results and conclusions.  Likewise, adherence to self-care treatments in the 
SDSCA (i.e., diet, exercise, and SMBG) could be measured in many various ways, which 
might yield different results. 
     Future research could also explore if “harm” and “benefit” is too simplistic.  Risk 
perception was separated into those opposing constructs for this study because of 
previous research on the topic (Fischoff et al., 1978; Slovic et al., 2007) and the desire to 
have study questions that the general public could comprehend.  Moreover, optimism bias 
has been noted in previous risk perception research (Walker et al., 2003), and the harm 
and benefit perception questions asked in this particular study might have elicited similar 
biases.  
     Previous research has found that risk perception differs between different 
races/ethnicities (Slovic, 2007).  It was decided not to include race as a control variable in 
this study because of the geographic location of the sample, which would yield such a 
small proportion of non-white respondents as to render sub-analyses based on race 
meaningless and/or difficult to interpret.  Therefore, future research could explore both if 
race and if geographic location influences risk perception and adherence to treatments.   
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Conclusion 
 Much research has been conducted to elucidate the causes of nonadherence and 
methods for improving adherence to diabetes-related treatments; yet, adherence remains 
woefully poor through all sectors of society.  Gaining insight into how persons who live 
with a diagnosis of T2DM perceive the harms and benefits of diabetes-related self-care 
treatments in relation to other medical and nonmedical products and activities may help 
with other areas of diabetes treatment adherence research.  
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Appendix 1. Risk Perception Items 
 
 
 
 
 
 
 
 
 
 
   93 
 
Appendix 2. Perceived Threat Subscale of the Cognitive Appraisal of Health Scale 
 
 strongly 
disagree 
1 
disagree 
2 
undecided 
3 
agree 
4 
strongly 
agree 
5 
Diabetes is frightening to 
me. 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
Things will only get worse 
because of having diabetes. 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
My diabetes will not go 
well. 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
I have a lot to lose because 
of having diabetes. 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
I worry about what will 
happen to me. 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
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Appendix 3. 8-Item Morisky Medication Adherence Scale 
 
Do you sometimes forget to take your diabetes pills? 
     ☐ Yes          No 
People sometimes miss taking their medications for reasons other than forgetting.  
Thinking over the past two weeks, were there any days when you did not take your 
diabetes medicine? 
       Yes          No 
Have you ever cut back or stopped taking your medication without telling your 
doctor, because you felt worse when you took it? 
       Yes          No 
When you travel or leave home, do you sometimes forget to bring along your 
diabetes medication? 
       Yes          No 
Did you take your diabetes medicine yesterday? 
       Yes          No 
When you feel like your diabetes is under control, do you sometimes stop taking 
your medicine? 
       Yes          No 
Taking medication everyday is a real inconvenience for some people.  Do you ever 
feel hassled about sticking to your diabetes treatment plan? 
       Yes          No 
How often do you have difficulty remembering to take all your medications? 
       Never/Rarely        
       Once in a while 
       Sometimes  
       Usually 
       All the time 
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Appendix 4. Summary of Diabetes Self-Care Activities Scale 
 
Diet Days 
How many of the last SEVEN DAYS have you 
followed a healthful eating plan? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On average, over the past month, how many 
DAYS PER WEEK have you followed your 
eating plan? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On how many of the last SEVEN DAYS did 
you eat five or more servings of fruits and 
vegetables? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On how many of the last SEVEN DAYS did 
you eat high fat foods such as red meat or 
full-fat dairy products? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
Exercise 
On how many of the last SEVEN DAYS did 
you participate in at least 30 minutes of physical 
activity? (Total minutes of continuous 
activity, including walking). 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On how many of the last SEVEN DAYS did 
you participate in a specific exercise session 
(such as swimming, walking, biking) other than 
what you do around the house or as part of your 
work? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
Blood Sugar Testing 
On how many of the last SEVEN DAYS did 
you test your blood sugar? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On how many of the last SEVEN DAYS did 
you test your blood sugar the number of 
times recommended by your health care 
provider? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
Foot Care 
On how many of the last SEVEN DAYS did 
you check your feet? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
On how many of the last SEVEN DAYS did 
you inspect the inside of your shoes? 
☐ 
0 
☐ 
1 
☐ 
2 
☐ 
3 
☐ 
4 
☐ 
5 
☐ 
6 
☐ 
7 
Smoking	 
Have you smoked a cigarette—even one puff—
during the past SEVEN DAYS? 
☐ 
No 
☐ 
Yes 
If you answered yes above, how many cigarettes       
did you smoke on an average day? Number	  of	  cigarettes:________	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Appendix 5. Diabetes Empowerment Scale—Short Form 
 
                                            
In general, I believe 
that I: 
 
strongly 
disagree 
1 
disagree 
2 
undecided 
3 
agree 
4 
strongly 
agree 
5 
a. ...know what part(s) of 
taking care of my 
diabetes that I am 
dissatisfied with. 
  
1 
  
2 
  
3 
  
4 
  
5 
 b. …am able to turn my 
diabetes goals into a 
workable plan. 
  
1 
  
2 
  
3 
  
4 
  
5 
 c.  ...can try out different 
ways of overcoming 
barriers to my diabetes 
goals. 
  
1 
  
2 
  
3 
  
4 
  
5 
 d.  ...can find ways to feel 
better about having 
diabetes. 
  
1 
  
2 
  
3 
  
4 
  
5 
 e.  ...know the positive 
ways I cope with 
diabetes-related stress. 
  
1 
  
2 
  
3 
  
4 
  
5 
 f.  ...can ask for support 
for having and caring 
for my diabetes when 
I need it. 
  
1 
  
2 
  
3 
  
4 
  
5 
 g.  ...know what helps me 
stay motivated to care 
for my diabetes. 
  
1 
  
2 
  
3 
  
4 
  
5 
 h.  ...know enough about 
myself as a person to 
make diabetes care 
choices that are right 
for me. 
  
1 
  
2 
  
3 
  
4 
  
5 
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Appendix 6. Online-based Survey 
 
Dear Essentia Health Patient: 
 
I am writing to ask for your help in a health study by completing the attached 
questionnaire. This study is being conducted at the Essentia Institute of Rural Health in 
collaboration with the University of Minnesota-Duluth. The purpose of this study is to 
better understand how opinions of different risks effect decisions to follow suggested 
medical treatments in people with type II diabetes mellitus. The ultimate goal is to help 
improve the communication and education health care professionals provide to their 
patients.You have been randomly selected for this study. All patients with diabetes who 
have received care with an Essentia Health affiliated clinic for at least one year were 
eligible to be randomly selected. Your participation in the study is voluntary, and your 
answers are private and confidential. Only the overall results will be reported. Your name 
will never be associated with the answers you provide. The questionnaire should take less 
than 20 minutes of your time.If you have any questions about the survey, please feel free 
to contact Dr. Steve Waring at 218-786-1280.This study has been reviewed and approved 
by the Essentia Health Institutional Review Board regarding research on human subjects 
study #EH14351. If you have a question about this aspect of the study, please call the 
IRB office at 218-786-3215.  For questions about your rights as a research participant, 
contact Ms. Vicki Clevenger, Vice President, Compliance & Audit/Chief Compliance 
Officer for Essentia Health, at 218-786-3539.In closing, I would like to emphasize your 
importance in this study. Your answers will help to understand the issues that people with 
diabetes face when treating diabetes. Please participate if you can. 
 
Sincerely, 
 
Stephen Waring, DVM, PhD 
Senior Research Scientist 
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Q43 Would you like to take the survey? 
m Yes	  (1)	  
m No	  (2)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  End	  of	  Survey	  
 
Q37 Have you been told that you have type 2 diabetes (formerly called adult-onset 
diabetes)? 
m Yes	  (1)	  
m No	  (2)	  If	  Yes	  Is	  Selected,	  Then	  Skip	  To	  Do	  you	  currently	  use	  oral	  medications...	  
 
Q39 Do you have diabetes? 
m Yes	  (1)	  
m No	  (2)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  Do	  you	  currently	  use	  oral	  medications...	  
 
Q41 What type of diabetes do you have?  Please enter in the space below.  Please say 
"unsure" if you do not know the type of diabetes that you have. 
 
Q1 Do you currently use oral medications to treat diabetes? 
m Yes	  (1)	  
m No	  (2)	  
 
Q2 Do you currently use insulin to treat diabetes? 
m Yes	  (1)	  
m No	  (2)	  
 
Q5 For this question, please only consider the medications you take for diabetes.  Over 
the previous 5 years have you experienced side effects from DIABETES medications? 
m Yes	  (1)	  
m No	  (2)	  
m Unsure	  if	  side	  effects	  were	  caused	  by	  diabetes	  medications	  (3)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  Thinking	  about	  the	  previous	  5	  years,	  ...If	  Unsure	  if	  side	  effects	  were...	  Is	  Selected,	  Then	  Skip	  To	  Thinking	  about	  the	  side	  effects	  you	  p...	  
 
Q6 Thinking about the side effects you experienced in the previous 5 years from diabetes 
medications, overall would you say that the severity of the side effects were: 
m Mild	  (1)	  
m Moderate	  (2)	  
m Severe	  (3)	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 If	  Mild	  Is	  Selected,	  Then	  Skip	  To	  Again,	  think	  about	  the	  previous	  5	  yea...If	  Moderate	  Is	  Selected,	  Then	  Skip	  To	  Again,	  think	  about	  the	  previous	  5	  yea...If	  Severe	  Is	  Selected,	  Then	  Skip	  To	  Again,	  think	  about	  the	  previous	  5	  yea...	  
 
Q38 Thinking about the side effects you possibly experienced in the previous 5 years 
from diabetes medications, overall would you say that the severity of the side effects 
were: 
m Mild	  (1)	  
m Moderate	  (2)	  
m Severe	  (3)	  
Q3 Again, think about the previous 5 years, do you remember having side effects from 
ANY medications? 
m Yes	  (1)	  
m No	  (2)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  End	  of	  Block	  
 
Q4 Overall, would you say that the severity of the side effects you experienced over the 
last 5 years were: 
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m Mild	  (1)	  
m Moderate	  (2)	  
m Severe	  (3)	  
 
Q7 Individuals have identified many issues regarding their use of medications and we are 
interested in your experiences.  There are no right or wrong answers.  Please answer each 
question based on your personal experience with diabetes. 	   Yes	  (1)	   No	  (2)	  
Do you sometimes forget to 
take your diabetes pills? (1) m 	   m 	  
People sometimes miss 
taking their medications for 
reasons other than 
forgetting. Thinking over the 
past TWO WEEKS, were 
there any days when you did 
not take your diabetes 
medicine? (2) 
m 	   m 	  
Have you ever cut back or 
stopped taking your 
medication without telling 
your doctor because you felt 
worse when you took it? (3) 
m 	   m 	  
When you travel or leave 
home, do you sometimes 
forget to bring along your 
diabetes medication? (4) 
m 	   m 	  
Did you take your diabetes 
medicine yesterday? (5) m 	   m 	  
When you feel like your 
diabetes is under control, do 
you sometimes stop taking 
your medicine? (6) 
m 	   m 	  
Taking medication everyday 
is a real inconvenience for 
some people. Do you ever 
feel hassled about sticking to 
your diabetes treatment 
plan? (7) 
m 	   m 	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Q8 How often do you have difficulty remembering to take all of your medications? 
m Never/Rarely	  (1)	  
m Once	  in	  a	  while	  (2)	  
m Sometimes	  (3)	  
m Usually	  (4)	  
m All	  the	  time	  (5)	  
 
Q9 In this section, please answer how much you agree or disagree with the following 
questions regarding how you feel about diabetes. 	   Strongly	  Disagree	  (1)	   Disagree	  (2)	   Undecided	  (3)	   Agree	  (4)	   Strongly	  Agree	  (5)	  
Diabetes is 
frightening 
to me. (1) 
m 	   m 	   m 	   m 	   m 	  
Things will 
only get 
worse 
because of 
having 
diabetes. (2) 
m 	   m 	   m 	   m 	   m 	  
My diabetes 
will not go 
well. (3) 
m 	   m 	   m 	   m 	   m 	  
I have a lot 
to lose 
because of 
having 
diabetes. (4) 
m 	   m 	   m 	   m 	   m 	  
I worry 
about what 
will happen 
to me. (5) 
m 	   m 	   m 	   m 	   m 	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Q10 This next section is going to include a list of medications, medical tests and 
procedures, and other nonmedical items or activities.  Please consider the potential 
negative effects of the items or activities. Specifically, to what extent would you say that 
people who are exposed to (or use) this item are at risk of experiencing personal harm 
from it?  Possible answers range from 1 to 7, with 1 equaling Not at Risk and 7 equaling 
Very Much at Risk. 	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Drugs for 
depression 
(1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
erectile 
dysfunction 
(Viagra) (2) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
epilepsy (3) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Influenza 
vaccination 
(4) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
osteoporosis 
(5) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Sleeping pills 
(6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
asthma (7) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
NSAIDS 
(Advil or 
Aleve) (8) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Insulin (9) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Vitamin pills 
(10) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Diet drugs 
(11) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Vaccines (12) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
Alzheimer's 
disease (13) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
anxiety (14) m 	   m 	   m 	   m 	   m 	   m 	   m 	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Nicotine 
replacement 
(patches) (15) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Herbal 
medicines 
(16) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Cancer 
chemotherapy 
(17) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Aspirin (18) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
cholesterol 
(19) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Prescription 
drugs (20) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Blood 
pressure 
drugs (21) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
diabetes 
(non-insulin) 
(22) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Over-the-
counter 
(OTC) drugs 
(23) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
neuropathy 
(nerve pain) 
(24) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	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Q11 As a reminder, the question being asked is: To what extent would you say that 
people who are exposed to (or use) this item are at risk of experiencing personal harm 
from it?   	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Prostate 
screening 
tests (1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Mammogram 
(2) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Heart 
surgery (3) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Medical x-
rays (4) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Self-
monitoring 
of blood 
glucose 
(using 
lancets) (5) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Acupuncture 
(6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
 
Q12 Again, please answer the following question: To what extent would you say that 
people who are exposed to (or use) this item or activity are at risk of experiencing 
personal harm from it? 	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Cell phones 
(1) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Cigarette 
smoking (2) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
High-fat 
foods (3) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Automobiles 
(4) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Air travel 
(5) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Coffee (6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Electronic 
cigarettes 
(7) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	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Household 
cleaners (8) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Food 
additives (9) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Alcoholic 
beverages 
(10) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Moderate-
intensity 
exercise 
(11) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Artificial 
sweeteners 
(12) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Pesticides 
(13) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
High-sugar 
foods (14) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Genetically 
modified 
foods (15) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Nuclear 
power plants 
(16) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
 
Q13 This next section is going to include the same list of medications, medical tests and 
procedures, and other nonmedical items or activities as the previous section.  This time, 
we ask that you consider the potential positive effects of using the items or activities.  In 
general, how beneficial do you consider this item or activity to be?  Similar to the 
previous section, possible answers will range from 1 to 7, but in this section, 1 will equal 
Not at All Beneficial and 7 will equal Very Beneficial. 	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Drugs for 
depression 
(1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
erectile 
dysfunction 
(Viagra) (2) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for m 	   m 	   m 	   m 	   m 	   m 	   m 	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epilepsy (3) 
Influenza 
vaccination 
(4) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
osteoporosis 
(5) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Sleeping pills 
(6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
asthma (7) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
NSAIDS 
(Advil or 
Aleve) (8) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Insulin (9) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Vitamin pills 
(10) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Diet drugs 
(11) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Vaccines (12) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
Alzheimer's 
disease (13) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
anxiety (14) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Nicotine 
replacement 
(patches) (15) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Herbal 
medicines 
(16) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Cancer 
chemotherapy 
(17) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Aspirin (18) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
cholesterol 
(19) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Prescription m 	   m 	   m 	   m 	   m 	   m 	   m 	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drugs (20) 
Blood 
pressure 
drugs (21) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
diabetes 
(non-insulin) 
(22) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Over-the-
counter 
(OTC) drugs 
(23) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Drugs for 
neuropathy 
(nerve pain) 
(24) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
 
 
Q14 As a reminder, the question being asked is: In general, how beneficial do you 
consider this item or activity to be?    	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Prostate 
screening 
tests (1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Mammogram 
(2) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Heart 
surgery (3) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Medical x-
rays (4) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Self-
monitoring 
of blood 
glucose 
(using 
lancets) (5) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Acupuncture 
(6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
 
 
   108 
 
Q15 Again, please answer the following question: In general, how beneficial do you 
consider this item or activity to be?  	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	   6	  (6)	   7	  (7)	  
Cell phones 
(1) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Cigarette 
smoking (2) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
High-fat 
foods (3) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Automobiles 
(4) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Air travel 
(5) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Coffee (6) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Electronic 
cigarettes 
(7) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Household 
cleaners (8) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Food 
additives (9) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Alcoholic 
beverages 
(10) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Moderate-
intensity 
exercise 
(11) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Artificial 
sweeteners 
(12) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Pesticides 
(13) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
High-sugar 
foods (14) m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Genetically 
modified 
foods (15) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	  
Nuclear m 	   m 	   m 	   m 	   m 	   m 	   m 	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power plants 
(16) 
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Q34 The questions below ask about your diabetes self-care activities during the past 7 
days.  If you were sick during the past 7 days, please think back to the last 7 days that you 
were not sick. 
 
Q16 Diet 	   0	  Days	  (1)	   1	  Day	  (2)	   2	  Days	  (3)	   3	  Days	  (4)	   4	  Days	  (5)	   5	  Days	  (6)	   6	  Days	  (7)	   7	  Days	  (8)	  
How many 
of the last 
SEVEN 
DAYS 
have you 
followed a 
healthful 
eating 
plan? (1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On 
average, 
over the 
past month, 
how many 
DAYS 
PER 
WEEK 
have you 
followed 
your eating 
plan? (2) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On how 
many of 
the last 
SEVEN 
DAYS did 
you eat 
five or 
more 
servings of 
fruits and 
vegetables? 
(3) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On how 
many of m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	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the last 
SEVEN 
DAYS did 
you eat 
high fat 
foods such 
as red meat 
or full-fat 
dairy 
products? 
(4) 
 
Q18 Exercise 	   0	  Days	  (1)	   1	  Day	  (2)	   2	  Days	  (3)	   3	  Days	  (4)	   4	  Days	  (5)	   5	  Days	  (6)	   6	  Days	  (7)	   7	  Days	  (8)	  
On how 
many of 
the last 
SEVEN 
DAYS did 
you 
participate 
in at least 
30 minutes 
of physical 
activity? 
(Total 
minutes of 
continuous 
activity, 
including 
walking). 
(1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On how 
many of 
the last 
SEVEN 
DAYS did 
you 
participate 
in a 
specific 
exercise 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	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session 
(such as 
swimming, 
walking, 
biking) 
other than 
what you 
do around 
the house 
or as part 
of your 
work? (2) 
 
 
Q19 Blood Sugar Testing 	   0	  Days	  (1)	   1	  Day	  (2)	   2	  Days	  (3)	   3	  Days	  (4)	   4	  Days	  (5)	   5	  Days	  (6)	   6	  Days	  (7)	   7	  Days	  (8)	  
On how many 
of the last 
SEVEN 
DAYS did 
you test your 
blood sugar? 
(1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On how many 
of the last 
SEVEN 
DAYS did 
you test your 
blood sugar 
the number of 
times 
recommended 
by your 
health care 
provider? (2) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	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Q20 Foot Care 	   0	  Days	  (1)	   1	  Day	  (2)	   2	  Days	  (3)	   3	  Days	  (4)	   4	  Days	  (5)	   5	  Days	  (6)	   6	  Days	  (7)	   7	  Days	  (8)	  
On how 
many of 
the last 
SEVEN 
DAYS 
did you 
check 
your 
feet? (1) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
On how 
many of 
the last 
SEVEN 
DAYS 
did you 
inspect 
the 
inside 
of your 
shoes? 
(2) 
m 	   m 	   m 	   m 	   m 	   m 	   m 	   m 	  
 
 
Q21 Have you smoked a cigarette--even one puff--during the past SEVEN DAYS? 
m Yes	  (1)	  
m No	  (2)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  End	  of	  Block	  
 
Q22 How many cigarettes did you smoke on an average day?  Please enter your response 
as a whole number (ex. 8) in the box below. 
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Q23 Please answer how much you agree or disagree with the following questions. In 
general, I believe that: 	   Srongly	  Disagree	  (1)	   Disagree	  (2)	   Undecided	  (3)	   Agree	  (4)	   Strongly	  	  	  	  	  	  	  Agree	  (5)	  
I know what 
part(s) of 
taking care 
of my 
diabetes that 
I am 
dissatisfied 
with. (1) 
m 	   m 	   m 	   m 	   m 	  
I am able to 
turn my 
diabetes 
goals into a 
workable 
plan. (2) 
m 	   m 	   m 	   m 	   m 	  
I can try out 
different 
ways of 
overcoming 
barriers to 
my diabetes 
goals. (3) 
m 	   m 	   m 	   m 	   m 	  
I can find 
ways to feel 
better about 
having 
diabetes. (4) 
m 	   m 	   m 	   m 	   m 	  
I know the 
positive ways 
I cope with 
diabetes-
related stress. 
(5) 
m 	   m 	   m 	   m 	   m 	  
I can ask for 
support for 
having and 
caring for my 
diabetes 
when I need 
m 	   m 	   m 	   m 	   m 	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it. (6) 
I know what 
helps me stay 
motivated to 
care for my 
diabetes. (7) 
m 	   m 	   m 	   m 	   m 	  
I know 
enough about 
myself as a 
person to 
make 
diabetes care 
choices that 
are right for 
me. (8) 
m 	   m 	   m 	   m 	   m 	  
 
Q25 What is your current age in years? Select "I prefer not to answer" found at the 
bottom of the drop down list if you do not wish to share your age. 
m 21	  (1)	  
m …	  
m 100	  (80)	  
m I	  prefer	  not	  to	  answer	  (81)	  
 
Q26 Gender 
m Male	  (1)	  
m Female	  (2)	  
m I	  prefer	  not	  to	  answer	  (3)	  
 
Q27 At what age were you first told you had diabetes? 
m 0	  (1)	  
m …	  
m 100	  (101)	  
 
Q28 Relationship Status 
m Single	  (1)	  
m Married	  (2)	  
m Divorced	  (3)	  
m Separated	  (4)	  
m Widowed	  (5)	  
m Committed	  Relationship	  (unmarried)	  (6)	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Q29 Current Weight: Pounds	  (1)	  
 
Q30 Current Height: Feet	  (1)	  Inches	  (2)	  
 
Q31 We are interested in knowing your most recent hemoglobin A1C (HbA1C) and the 
date it was measured.  The HbA1C is a measure of long-term diabetes control and is 
written as a percentage.  Do you know your most recent HbA1C value? 
m Yes	  (1)	  
m No	  (2)	  If	  No	  Is	  Selected,	  Then	  Skip	  To	  Annual	  Household	  Income	  
 
Q32 Please enter your most recent HbA1C value and the date it was measured.  If you are 
unsure of the date of your most recent HbA1C test, please leave the date space blank. HbA1C	  %	  (1)	  Date	  HbA1C	  Measured	  (mm/dd/yyyy)	  (2)	  
 
Q33 Annual Household Income: 
m Less	  than	  $10,000	  (1)	  
m $10,000-­‐$19,999	  (2)	  
m $20,000-­‐29,999	  (3)	  
m $30,000-­‐39,999	  (4)	  
m $40,000-­‐49,999	  (5)	  
m $50,000-­‐59,999	  (6)	  
m $60,000-­‐69,999	  (7)	  
m $70,000-­‐79,999	  (8)	  
m $80,000-­‐89,999	  (9)	  
m $90,000-­‐99,999	  (10)	  
m $100,000-­‐109,999	  (11)	  
m $110,000-­‐119,999	  (12)	  
m $120,000-­‐129,999	  (13)	  
m $130,000-­‐139,999	  (14)	  
m $140,000-­‐149,999	  (15)	  
m greater	  than	  or	  equal	  to	  $150,000	  (16)	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Q34 Highest level of education completed: 
m Less	  than	  high	  school	  (1)	  
m High	  school	  graduate	  or	  GED	  (2)	  
m Some	  college,	  community,	  or	  technical	  school	  (3)	  
m Community	  or	  technical	  school	  graduate	  (4)	  
m College	  graduate	  (5)	  
m Master's	  degree	  (6)	  
m Doctoral	  degree	  (7)	  
 
Q35 Have you ever had a visit with a certified diabetes educator (CDE)? 
m Yes	  (1)	  
m No	  (2)	  
m Unsure	  (3)	  
 
 
